138 - shodhgangashodhganga.inflibnet.ac.in/.../16/16_references.pdf · stewart fa. photodynamic...

138

Gene polymorphism and risk of oral cancer in a South Indian population – a case control study

REFERENCES

1. Jhavar S, Sarin R, Mulherkar R, Benner A, Agarwal JP,

Dinshaw K. Glutathione S-transferase M1 or T1 null

genotype as a risk factor for developing multiple primary

neoplasms in the upper aero -digestive tract, in Indian

males using tobacco. Oral Oncol. 2004 Jan;40(1):84 -91.

2. Copper MP, Triesscheijn M, Tan IB, Ruevekamp MC,

Stewart FA. Photodynamic therapy in the treatment of

multiple primary tumours in the head and neck, located

to the oral cavity and oropharynx. Clin Otolaryngol. 2007

Jun;32(3):185-9.

3. WHO. International Statist ical Classif ication of Diseases

and Related Health Problems. . 10th Revision, 2nd ed,

Geneva: WHO. 2003.

4. Macpherson LM, McCann MF, Gibson J, Binnie VI,

Stephen KW. The role of primary healthcare

professionals in oral cancer prevention and detection. Br

Dent J. 2003 Sep 13;195(5):277-81; discussion 63.

5. Thompson L. World Health Organization classif icat ion of

tumours: pathology and genetics of head and neck

tumours. Ear Nose Throat J. 2006 Feb;85(2):74.

6. Gale N, Michaels L, Luzar B, Poljak M, Zidar N,

Fischinger J, et al. Current review on squamous

intraepithelial lesions of the larynx. Histopathology. 2009

May;54(6):639-56.

7. Sarode SC, Sarode GS, Karmarkar S, Tupkari JV. A new

classif icat ion for potential ly malignant disorders of the

oral cavity. Oral Oncol. 2011 Jun 27.

8. Dias GS, Almeida AP. A histological and clinical study on

oral cancer: descriptive analyses of 365 cases. Med Oral

Patol Oral Cir Bucal. 2007 Dec;12(7):E474-8.

139


9. Stokes A. Comment on "Oral Oncology editorial --

Continued misrepresentation of KB cel ls as being of oral

cancer phenotype requires act ion" [O'Neill ID. Oral Oncol

2009;45(10):e117-118]. Oral Oncol. 2010 May;46(5):e38.

10. Yanofsky VR, Mercer SE, Phelps RG. Histopathological

variants of cutaneous squamous cell carcinoma: a

review. J Skin Cancer. 2011;2011:210813.

11. Quaedvlieg PJ, Creytens DH, Epping GG, Peutz -Kootstra

CJ, Nieman FH, Thissen MR, et al. Histopathological

characteristics of metastasizing squamous cell

carcinoma of the skin and lips. Histopathology. 2006

Sep;49(3):256-64.

12. Chen RB, Suzuki K, Nomura T, Nakajima T. Flow

cytometric analysis of squamous cell carcinomas of the

oral cavity in relat ion to lymph node metastasis. J Oral

Maxil lofac Surg. 1993 Apr;51(4):397 -401.

13. Al-Rawi NH, Talabani NG. Squamous cell carcinoma of

the oral cavity: a case series analysis of clinical

presentat ion and histological grading of 1,425 cases from

Iraq. Clin Oral Investig. 2008 Mar;12(1):15 -8.

14. Cardesa A, Gale N, Nadal A, Zidar N. Squamous cell

carcinoma. In: Barnes L, Eveson JW, Reichart P,

Sidransky D (Eds): World Health Organization

Classif icat ion of Tumours. Pathology & Genetics. Head

and Neck Tumours. IARC Press: Lyon, 2005. 2005:

119-23.

15. Silveira EJ, Godoy GP, Lins RD, Arruda Mde L, Ramos

CC, Freitas Rde A, et al. Correlation of cl inical,

histological, and cytokerat in prof i les of squamous cell

carcinoma of the oral tongue with prognosis. Int J Surg

Pathol. 2007 Oct;15(4):376-83.

16. Fang KH, Kao HK, Cheng MH, Chang YL, Tsang NM,

Huang YC, et al. Histological dif ferentiation of primary

140


oral squamous cell carcinomas in an area of betel quid

chewing prevalence. Otolaryngol Head Neck Surg. 2009

Dec;141(6):743-9.

17. Zhang Z, Helman JI, Li LJ. Lymphangiogenesis,

lymphatic endothelial cells and lymphatic metastasis in

head and neck cancer--a review of mechanisms. Int J

Oral Sci. 2010 Mar;2(1):5 -14.

18. Lim YC, Kim WS, Choi EC. Collision metastasis of

squamous carcinoma of the oral tongue and incidental

thyroid papil lary carcinoma to a single cervical lymph

node. Int J Oral Maxil lofac Surg. 2008 May;37(5):494 -6.

19. Nithya C, Pandey M, Naik B, Ahamed IM. Patterns of

cervical metastasis from carcinoma of the oral tongue.

World J Surg Oncol. 2003 Jul 3;1(1):10.

20. Jerjes W, Upile T, Petrie A, Riskalla A, Hamdoon Z,

Vourvachis M, et al. Clinicopathological parameters,

recurrence, locoregional and distant metastasis in 115

T1-T2 oral squamous cell carcinoma patients. Head Neck

Oncol. 2010;2:9.

21. Woolgar JA, Triantafyl lou A. Pitfalls and procedures in

the histopathological diagnosis of oral and oropharyngeal

squamous cell carcinoma and a review of the role of

pathology in prognosis. Oral Oncol. 2009 Apr -May;45(4-

5):361-85.

22. Swinson B, Jerjes W, El-Maaytah M, Norris P, Hopper C.

Optical techniques in diagnosis of head and neck

malignancy. Oral Oncol. 2006 Mar;42(3):221-8.

23. Upile T, Jerjes W, Betz CS, El Maaytah M, Wright A,

Hopper C. Optical diagnostic techniques in the head and

neck. Dent Update. 2007 Sep;34(7):410-2, 5-6, 9-20

passim.

141


24. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer

statistics, 2002. CA Cancer J Clin. 2005 Mar -

Apr;55(2):74-108.

25. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the

world cancer burden: Globocan 2000. Int J Cancer. 2001

Oct 15;94(2):153-6.

26. Franceschi S, Bidoli E, Herrero R, Munoz N. Comparison

of cancers of the oral cavity and pharynx worldwide:

etiological clues. Oral Oncol. 2000 Jan;36(1):106 -15.

27. Mayne ST, Cartmel B, Kirsh V, Goodwin WJ, Jr. Alcohol

and tobacco use prediagnosis and postdiagnosis, and

survival in a cohort of patients with early stage cancers

of the oral cavity, pharynx, and larynx. Cancer Epidemiol

Biomarkers Prev. 2009 Dec;18(12):3368-74.

28. McDowell JD. An overview of epidemiology and common

risk factors for oral squamous cell carcinoma.

Otolaryngol Clin North Am. 2006 Apr;39(2):277 -94.

29. Muwonge R, Ramadas K, Sankila R, Thara S, Thomas G,

Vinoda J, et al. Role of tobacco smoking, chewing and

alcohol drinking in the risk of oral cancer in Trivandrum,

India: a nested case-control design using incident cancer

cases. Oral Oncol. 2008 May;44(5):446-54.

30. Warnakulasuriya S, Scully C. Comprehending the

condition, causes, controversies, control and

consequences. 2. Main risk factors and epidemiology.

Dent Update. 2010 Dec;37(10):710-2.

31. Morger R, Ramseier CA, Rees TD, Burgin WB, Bornstein

MM. Oral mucosal f indings related to tobacco use and

alcohol consumption: a study on Swiss army recruits

involving self -reported and clinical data. Oral Health Prev

Dent. 2010;8(2):143-51.

32. Canova C, Richiardi L, Merlett i F, Pentenero M, Gervasio

C, Tanturri G, et al. Alcohol, tobacco and genetic

142


susceptibi l ity in relat ion to cancers of the upper

aerodigestive tract in northern Italy. Tumori. 2010 Jan -

Feb;96(1):1-10.

33. Scutariu MM, Voroneanu M, Ursache M. [Detection

strategies and risk factors in oral cancers]. Rev Med Chir

Soc Med Nat Iasi. 2007 Jan-Mar;111(1):221-7.

34. IARC. International Agency for Research on Cancer

Tobacco smoking IARC Monograph on the evaluation of

carcinogenic r isks of chemicals to humans 1986;38:

1-421.

35. Protano C, Andreoli R, Manini P, Guidotti M, Vital i M. A

tobacco-related carcinogen: assessing the impact of

smoking behaviours of cohabitants on benzene exposure

in chi ldren. Tob Control. 2011 Jul 5.

36. Palmer R, Scully C, Felix DH. Nicotine, smoke and

patches. Br Dent J. 2006 Jan 28;200(2):65.

37. Gil l ison ML. Current topics in the epidemiology of oral

cavity and oropharyngeal cancers. Head Neck. 2007

Aug;29(8):779-92.

38. Warnakulasuriya KA, Ralhan R. Clinical, pathological,

cellular and molecular lesions caused by oral smokeless

tobacco--a review. J Oral Pathol Med. 2007

Feb;36(2):63-77.

39. Ahluwalia K, Ro M, Erwin K, Treadwell H. Racial

disparit ies in oral cancer risk and outcomes. J Cancer

Educ. 2005 Summer;20(2):70-1.

40. Ahluwalia KP. Assessing the oral cancer r isk of South -

Asian immigrants in New York City. Cancer. 2005 Dec

15;104(12 Suppl):2959-61.

41. Weitkunat R, Sanders E, Lee PN. Meta-analysis of the

relat ion between European and American smokeless

tobacco and oral cancer. BMC Public Health. 2007;7:334.

143


42. Lambert R, Sauvaget C, de Camargo Cancela M,

Sankaranarayanan R. Epidemiology of cancer f rom the

oral cavity and oropharynx. Eur J Gastroenterol Hepatol.

2011 Aug;23(8):633-41.

43. Akhtar S, Sheikh AA, Qureshi HU. Chewing areca nut,

betel quid, oral snuff, cigarette smoking and the risk of

oesophageal squamous-cell carcinoma in South Asians:

A multicentre case-control study. Eur J Cancer. 2011

Jul 4.

44. Priebe SL, Aleksejuniene J, Zed C, Dharamsi S, Thinh

DH, Hong NT, et al. Oral squamous cell carcinoma and

cultural oral r isk habits in Vietnam. Int J Dent Hyg. 2010

Aug;8(3):159-68.

45. Merlett i F, Boffetta P, Ciccone G, Mashberg A, Terracini

B. Role of tobacco and alcoholic beverages in the

etiology of cancer of the oral cavity/oropharynx in Torino,

Italy. Cancer Res. 1989 Sep 1;49(17):4919-24.

46. Pelucchi C, Tramacere I, Boffetta P, Negri E, La Vec chia

C. Alcohol consumption and cancer risk. Nutr Cancer.

2011 Oct;63(7):983-90.

47. Giacosa A, Adam-Blondon AF, Baer-Sinnott S, Barale R,

Bavaresco L, Di Gaspero G, et al. Alcohol and wine in

relat ion to cancer and other diseases. Eur J Cancer

Prev. 2011 Oct 13.

48. Downer M. Where next in oral cancer prevention and

control? Community Dent Health. 2007 Jun;24(2):66 -9.

49. Lachenmeier DW, Monakhova YB. Short -term salivary

acetaldehyde increase due to direct exposure to

alcoholic beverages as an additional cancer risk factor

beyond ethanol metabolism. J Exp Clin Cancer Res.

2011;30:3.

50. Lee SY, Cho NH, Choi EC, Baek SJ, Kim WS, Shin DH,

et al. Relevance of human papil loma virus (HPV)

144


infection to carcinogenesis of oral tongue cancer. Int J

Oral Maxil lofac Surg. 2010 Jul;39(7):678-83.

51. Bleyer A. Cancer of the oral cavity and pharynx in young

females: increasing incidence, role of human papilloma

virus, and lack of survival improvement. Semin Oncol.

2009 Oct;36(5):451-9.

52. Hansson BG, Rosenquist K, Antonsson A, Wennerberg J,

Schildt EB, Bladstrom A, et al. Strong associat ion

between infection with human papil lomavirus and oral

and oropharyngeal squamous cell carcinoma: a

population-based case-control study in southern Sweden.

Acta Otolaryngol. 2005 Dec;125(12):1337-44.

53. Campisi G, Giovannell i L. Controversies surrounding

human papilloma virus infection, head & neck vs oral

cancer, implicat ions for prophylaxis and treatment. Head

Neck Oncol. 2009;1:8.

54. Pavia M, Pileggi C, Nobile CG, Angelil lo IF. Association

between fruit and vegetable consumption and oral

cancer: a meta-analysis of observational studies. Am J

Clin Nutr. 2006 May;83(5):1126-34.

55. Day GL, Shore RE, Blot WJ, McLaughlin JK, Austin DF,

Greenberg RS, et al. Dietary factors and second primary

cancers: a follow-up of oral and pharyngeal cancer

patients. Nutr Cancer. 1994;21(3):223 -32.

56. Maserejian NN, Giovannucci E, Rosner B, Zavras A,

Joshipura K. Prospective study of fruits and vegetables

and risk of oral premalignant lesions in men. Am J

Epidemiol. 2006 Sep 15;164(6):556 -66.

57. Nieto A, Sanchez MJ, Quintana MJ, Castellsague X,

Mart inez C, Munoz J, et al. BMI throughout l ife, intake of

vitamin supplements and oral cancer in Spain. IARC Sci

Publ. 2002;156:259-61.

145


58. Guha N, Boffetta P, Wunsch Filho V, Eluf Neto J,

Shangina O, Zaridze D, et al. Oral health and risk of

squamous cell carcinoma of the head and neck and

esophagus: results of two multicentric case -control

studies. Am J Epidemiol. 2007 Nov 15;166(10):1159 -73.

59. Lissowska J, Pilarska A, Pilarski P, Samolczyk -Wanyura

D, Piekarczyk J, Bardin-Mikollajczak A, et al. Smoking,

alcohol, diet, dentit ion and sexual pract ices in the

epidemiology of oral cancer in Poland. Eur J Cancer

Prev. 2003 Feb;12(1):25-33.

60. Shah N. Geriatric oral health issues in India. Int Dent J.

2001 Jun;51(3 Suppl) :212-8.

61. Vil la A, Kreimer AR, Pasi M, Polimeni A, Cicciu D,

Strohmenger L, et al. Oral cancer knowledge: a survey

administered to patients in dental departments at large

Italian hospitals. J Cancer Educ. 2011 Sep;26(3):505 -9.

62. Califano J, van der Riet P, Westra W, Nawroz H,

Clayman G, Piantadosi S, et al. Genetic progression

model for head and neck cancer: implicat ions for f ield

cancerizat ion. Cancer Res. 1996 Jun 1;56(11):2488 -92.

63. Yeh KT, Chang JG, Lin TH, Wang YF, Tien N, Chang JY,

et al. Epigenetic changes of tumor suppressor genes,

P15, P16, VHL and P53 in oral cancer. Oncol Rep. 2003

May-Jun;10(3):659-63.

64. Watanabe T, Wang X, Miyakawa A, Shiiba M, Imai Y,

Sato T, et al. Mutat ional state of tumor suppressor genes

(DCC, DPC4) and alterat ion on chromosome 18q21 in

human oral cancer. Int J Oncol. 1997 Dec;11(6):1287 -90.

65. Kim MS, Li SL, Bertolami CN, Cherrick HM, Park NH.

State of p53, Rb and DCC tumor suppressor genes in

human oral cancer cell l ines. Anticancer Res. 1993 Sep -

Oct;13(5A):1405-13.

146


66. Scully C. Oncogenes, onco-suppressors, carcinogenesis

and oral cancer. Br Dent J. 1992 Jul 25;173(2):53 -9.

67. Tadokoro K, Ueda M, Ohshima T, Fujita K, Rikimaru K,

Takahashi N, et al. Act ivat ion of oncogenes in human

oral cancer cel ls: a novel codon 13 mutation of c -H-ras-1

and concurrent amplif ications of c -erbB-1 and c-myc.

Oncogene. 1989 Apr;4(4):499-505.

68. Scully C, Bagan JV, Hopper C, Epstein JB. Oral cancer:

current and future diagnostic techniques. Am J Dent.

2008 Aug;21(4):199-209.

69. Liska D, Lyon M, Jones DS. Detoxif ication and

biotransformational imbalances. Explore (NY). 2006

Mar;2(2):122-40.

70. Dekant W. The role of biotransformation and

bioactivation in toxicity. EXS. 2009;99:57 -86.

71. Liska DJ. The detoxif icat ion enzyme systems. Altern Med

Rev. 1998 Jun;3(3):187-98.

72. Xu C, Li CY, Kong AN. Induction of phase I, II and II I

drug metabolism/transport by xenobiotics. Arch Pharm

Res. 2005 Mar;28(3):249-68.

73. Zienolddiny S, Campa D, Lind H, Ryberg D, Skaug V,

Stangeland LB, et al. A comprehensive analysis of phase

I and phase II metabolism gene polymorphisms and risk

of non-small cell lung cancer in smokers.

Carcinogenesis. 2008 Jun;29(6):1164-9.

74. Landi S, Gemignani F, Moreno V, Gioia -Patricola L,

Chabrier A, Guino E, et al. A comprehensive analysis of

phase I and phase II metabolism gene polymorphisms

and risk of colorectal cancer. Pharmacogenet Genomics.

2005 Aug;15(8):535-46.

75. Zhou S, Kestell P, Baguley BC, Paxton JW. Preclinical

factors inf luencing the relative contributions of Phase I

and II enzymes to the metabolism of the experimental

147


anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid.

Biochem Pharmacol. 2003 Jan 1;65(1):109-20.

76. Roos PH, Bolt HM. Cytochrome P450 interact ions in

human cancers: new aspects considering CYP1B1.

Expert Opin Drug Metab Toxicol. 2005 Aug;1(2):187 -202.

77. Kleiner HE, Vulimiri SV, Hatten WB, Reed MJ, Nebert

DW, Jefcoate CR, et al. Role of cytochrome p4501 family

members in the metabolic activation of polycycl ic

aromatic hydrocarbons in mouse epidermis. Chem Res

Toxicol. 2004 Dec;17(12):1667-74.

78. Shimada T, Fujii -Kuriyama Y. Metabolic act ivat ion of

polycycl ic aromatic hydrocarbons to carcinogens by

cytochromes P450 1A1 and 1B1. Cancer Sci. 2004

Jan;95(1):1-6.

79. Hildebrand CE, Gonzalez FJ, McBride OW, Nebert DW.

Assignment of the human 2,3,7,8-tetrachlorodibenzo-p-

dioxin-inducible cytochrome P1-450 gene to chromosome

15. Nucleic Acids Res. 1985 Mar 25;13(6) :2009-16.

80. Jaiswal AK, Gonzalez FJ, Nebert DW. Human P1 -450

gene sequence and correlat ion of mRNA with genetic

dif ferences in benzo[a]pyrene metabolism. Nucleic Acids

Res. 1985 Jun 25;13(12):4503-20.

81. Kawajir i K, Watanabe J, Gotoh O, Tagashira Y, Sogawa

K, Fuji i -Kuriyama Y. Structure and drug inducibil ity of the

human cytochrome P-450c gene. Eur J Biochem. 1986

Sep 1;159(2):219-25.

82. Hosoya T, Harada N, Mimura J, Motohashi H, Takahashi

S, Nakajima O, et al. Inducibi l ity of cytochrome P450 1A1

and chemical carcinogenesis by benzo[a]pyrene in AhR

repressor-deficient mice. Biochem Biophys Res Commun.

2008 Jan 18;365(3):562-7.

83. Dey A, Jones JE, Nebert DW. Tissue- and cell type-

specif ic expression of cytochrome P450 1A1 and

148


cytochrome P450 1A2 mRNA in the mouse locali zed in

situ hybridization. Biochem Pharmacol. 1999 Aug

1;58(3):525-37.

84. Singh N, Mitra AK, Garg VK, Agarwal A, Sharma M,

Chaturvedi R, et al. Associat ion of CYP1A1

polymorphisms with breast cancer in North Indian

women. Oncol Res. 2007;16(12):587 -97.

85. Kristiansen W, Haugen TB, Witczak O, Andersen JM,

Fossa SD, Aschim EL. CYP1A1, CYP3A5 and CYP3A7

polymorphisms and testicular cancer susceptibi l ity. Int J

Androl. 2011 Feb;34(1):77-83.

86. Wright CM, Larsen JE, Colosimo ML, Barr JJ, Chen L,

McLachlan RE, et al. Genetic associat ion study of

CYP1A1 polymorphisms identif ies r isk haplotypes in

nonsmall cell lung cancer. Eur Respir J. 2010

Jan;35(1):152-9.

87. Spurr NK, Gough AC, Stevenson K, Wolf CR. Msp -1

polymorphism detected with a cDNA probe for the P -450

I family on chromosome 15. Nucleic Acids Res. 1987 Jul

24;15(14):5901.

88. Crofts F, Cosma GN, Currie D, Taiol i E, Toniolo P, Garte

SJ. A novel CYP1A1 gene polymorphism in African -

Americans. Carcinogenesis. 1993 Sep;14(9):1729 -31.

89. Crofts F, Taiol i E, Trachman J, Cosma GN, Cu rrie D,

Toniolo P, et al. Functional signif icance of dif ferent

human CYP1A1 genotypes. Carcinogenesis. 1994

Dec;15(12):2961-3.

90. Cascorbi I , Brockmoller J, Roots I. A C4887A

polymorphism in exon 7 of human CYP1A1: populat ion

frequency, mutation linkages, and impact on lung cancer

susceptibi l ity. Cancer Res. 1996 Nov 1;56(21):4965 -9.

91. Hirvonen A, Husgafvel -Pursiainen K, Karjalainen A,

Antti la S, Vainio H. Point -mutational MspI and Ile -Val

149


polymorphisms closely l inked in the CYP1A1 gene: lack

of association with susceptibi l i ty to lung cancer in a

Finnish study population. Cancer Epidemiol Biomarkers

Prev. 1992 Sep-Oct;1(6):485-9.

92. Fontana X, Peyrottes I, Rossi C, Leblanc-Talent P, Ettore

F, Namer M, et al. Study of the frequencies of CYP1A1

gene polymorphisms and glutathione S-transferase mu1

gene in primary breast cancers: an update with an

additional 114 cases. Mutat Res. 1998 Jul 17;403(1 -2):

45-53.

93. Solus JF, Arietta BJ, Harris JR, Sexton DP, Steward JQ,

McMunn C, et al. Genetic variation in eleven phase I

drug metabolism genes in an ethnically diverse

population. Pharmacogenomics. 2004 Oct;5(7):895 -931.

94. Singhal R, Shankar K, Badger TM, Ronis MJ. Estrogenic

status modulates aryl hydrocarbon receptor --mediated

hepatic gene expression and carcinogenicity.

Carcinogenesis. 2008 Feb;29(2):227-36.

95. Hayashi S, Watanabe J, Nakachi K, Kawajir i K. Genetic

l inkage of lung cancer-associated MspI polymorphisms

with amino acid replacement in the heme binding region

of the human cytochrome P450IA1 gene. J Biochem.

1991 Sep;110(3):407-11.

96. Zhang ZY, Fasco MJ, Huang L, Guengerich FP,

Kaminsky LS. Characterization of purif ied human

recombinant cytochrome P4501A1-I le462 and -Val462:

assessment of a role for the rare allele in

carcinogenesis. Cancer Res. 1996 Sep 1;56(17):3926 -33.

97. Persson I, Johansson I, Ingelman-Sundberg M. In vitro

kinetics of two human CYP1A1 variant enzymes

suggested to be associated with interindividual

dif ferences in cancer susceptibi l ity. Biochem Biophys

Res Commun. 1997 Feb 3;231(1):227-30.

150


98. Chevalier D, Allorge D, Lo-Guidice JM, Cauff iez C,

Lhermitte M, Lafitte JJ, et al. Detection of known and two

novel (M331I and R464S) missense mutations in the

human CYP1A1 gene in a French Caucasian populat ion.

Hum Mutat. 2001 Apr;17(4):355.

99. Saito T, Egashira M, Kiyotani K, Fu jieda M, Yamazaki H,

Kiyohara C, et al. Novel nonsynonymous polymorphisms

of the CYP1A1 gene in Japanese. Drug Metab

Pharmacokinet. 2003;18(3):218-21.

100. London SJ, Yuan JM, Coetzee GA, Gao YT, Ross RK, Yu

MC. CYP1A1 I462V genetic polymorphism and lung

cancer risk in a cohort of men in Shanghai, China.

Cancer Epidemiol Biomarkers Prev. 2000 Sep;9(9):

987-91.

101. Chen S, Xue K, Xu L, Ma G, Wu J. Polymorphisms of the

CYP1A1 and GSTM1 genes in relation to individual

susceptibi l ity to lung carcinoma in Chinese populat ion.

Mutat Res. 2001 Jun;458(1-2):41-7.

102. Kawajir i K, Eguchi H, Nakachi K, Sekiya T, Yamamoto M.

Association of CYP1A1 germ l ine polymorphisms with

mutations of the p53 gene in lung cancer. Cancer Res.

1996 Jan 1;56(1):72-6.

103. Kawajir i K, Nakachi K, Imai K, Watanabe J, Hayashi S.

Germ l ine polymorphisms of p53 and CYP1A1 genes

involved in human lung cancer. Carcinogenesis. 1993

Jun;14(6):1085-9.

104. Song N, Tan W, Xing D, Lin D. CYP 1A1 polymorphism

and risk of lung cancer in relation to tobacco smoking: a

case-control study in China. Carcinogenesis. 2001

Jan;22(1):11-6.

105. Ozturk O, Isbir T, Yaylim I, Kocaturk CI, Gurses A. GST

M1 and CYP1A1 gene polymorphism and daily fruit

151


consumption in Turkish patients with non-small cell lung

carcinomas. In Vivo. 2003 Nov-Dec;17(6):625-32.

106. Sreelekha TT, Rajesh M, Anil Kumar V, Madhavan J,

Balaram P. CYP1A1m2 polymorphisms regulate estrogen

and interleukin-6 in lung cancer. Mol Med Report. 2010

Nov-Dec;3(6):971-6.

107. Tefre T, Ryberg D, Haugen A, Nebert DW, Skaug V,

Brogger A, et al. Human CYP1A1 (cytochrome P(1)450)

gene: lack of associat ion between the Msp I restrict ion

fragment length polymorphism and incidence of lung

cancer in a Norwegian populat ion. Pharmacogenetics.

1991 Oct;1(1):20-5.

108. Yuan X, Zhou G, Zhai Y, Xie W, Cui Y, Cao J, et al. Lack

of association between the functional polymorphisms in

the estrogen-metabolizing genes and risk for

hepatocellular carcinoma. Cancer Epidemiol Biomarkers

Prev. 2008 Dec;17(12):3621-7.

109. Wu MT, Lee JM, Wu DC, Ho CK, Wang YT, Lee YC, et al.

Genetic polymorphisms of cytochrome P4501A1 and

oesophageal squamous-cell carcinoma in Taiwan. Br J

Cancer. 2002 Aug 27;87(5):529-32.

110. Wang AH, Sun CS, Li LS, Huang JY, Chen QS.

Relat ionship of tobacco smoking CYP1A1 GSTM1 gene

polymorphism and esophageal cancer in Xi 'an. World J

Gastroenterol. 2002 Feb;8(1):49-53.

111. Wang AH, Sun CS, Li LS, Huang JY, Chen QS, Xu DZ.

Genetic susceptibil ity and environmental factors of

esophageal cancer in Xi'an. World J Gastroenterol. 2004

Apr 1;10(7):940-4.

112. Abbas A, Delvinquiere K, Lechevrel M, Lebail ly P,

Gauduchon P, Launoy G, et al. GSTM1, GSTT1, GSTP1

and CYP1A1 genetic polymorphisms and susceptibil ity to

esophageal cancer in a French population: dif ferent

152


pattern of squamous cell carcinoma and

adenocarcinoma. World J Gastroenterol. 2004 Dec

1;10(23):3389-93.

113. Morita S, Yano M, Shiozaki H, Tsujinaka T, Ebisui C,

Morimoto T, et al. CYP1A1, CYP2E1 and GSTM1

polymorphisms are not associated with susceptibi l ity to

squamous-cell carcinoma of the esophagus. Int J Cancer.

1997 Apr 10;71(2):192-5.

114. Wang LD, Zheng S, Liu B, Zhou JX, Li YJ, Li JX.

CYP1A1, GSTs and mEH polymorphisms and

susceptibi l ity to esophageal carcinoma: study of

population from a high- incidence area in north China.

World J Gastroenterol. 2003 Jul ;9(7):1394-7.

115. Jain M, Kumar S, Ghoshal UC, Mittal B. CYP1A1 Msp1

T/C polymorphism in esophageal cancer: no associat ion

and risk modulat ion. Oncol Res. 2007;16(9):437 -43.

116. Zhuo WL, Zhang YS, Wang Y, Zhuo XL, Zhu B, Cai L, et

al. Associat ion studies of CYP1A1 and GSTM1

polymorphisms with esophageal cancer risk: evidence -

based meta-analyses. Arch Med Res. 2009

Apr;40(3):169-79.

117. Lazarevic K, Nagorni A, Rancic N, Milut inovic S, Stosic

L, I l i jev I. Dietary factors and gastric cancer risk:

hospital-based case control study. J BUON. 2010 Jan-

Mar;15(1):89-93.

118. Roth MJ, Abnet CC, Johnson LL, Mark SD, Dong ZW,

Taylor PR, et al. Polymorphic variation of Cyp1A1 is

associated with the risk of gastric cardia cancer: a

prospective case-cohort study of cytochrome P-450 1A1

and GST enzymes. Cancer Causes Control. 2004

Dec;15(10):1077-83.

119. Suzuki S, Muroishi Y, Nakanishi I, Oda Y. Relationship

between genetic polymorphisms of drug-metabolizing

153


enzymes (CYP1A1, CYP2E1, GSTM1, and NAT2),

drinking habits, histological subtypes, and p53 gene

point mutations in Japanese patients with gastric cancer.

J Gastroenterol. 2004;39(3):220-30.

120. Darazy M, Balbaa M, Mugharbil A, Saeed H, Sidani H,

Abdel-Razzak Z. CYP1A1, CYP2E1, and GSTM1 gene

polymorphisms and susceptibil ity to colorectal and

gastric cancer among Lebanese. Genet Test Mol

Biomarkers. 2011 Jun;15(6):423-9.

121. Sivaraman L, Leatham MP, Yee J, Wilkens LR, Lau AF,

Le Marchand L. CYP1A1 genetic polymorphisms and in

situ colorectal cancer. Cancer Res. 1994 Jul

15;54(14):3692-5.

122. Slattery ML, Samowtiz W, Ma K, Murtaugh M, Sweeney

C, Levin TR, et al. CYP1A1, cigarette smoking, and colon

and rectal cancer. Am J Epidemiol. 2004 Nov

1;160(9):842-52.

123. Sachse C, Smith G, Wilkie MJ, Barrett JH, Waxman R,

Sull ivan F, et al. A pharmacogenetic study to investigate

the role of dietary carcinogens in the etiology of

colorectal cancer. Carcinogenesis. 2002

Nov;23(11):1839-49.

124. Kiss I, Sandor J, Pajkos G, Bogner B, Hegedus G, Ember

I. Colorectal cancer risk in relation to genetic

polymorphism of cytochrome P450 1A1, 2E1, and

glutathione-S-transferase M1 enzymes. Anticancer Res.

2000 Jan-Feb;20(1B):519-22.

125. Litt le J, Sharp L, Masson LF, Brockton NT, Cotton SC,

Haites NE, et al. Colorectal cancer and genetic

polymorphisms of CYP1A1, GSTM1 and GSTT1: a case -

control study in the Grampian region of Scotland. Int J

Cancer. 2006 Nov 1;119(9):2155-64.

154


126. Pereira Serafim PV, Cotrim Guerreiro da Silva ID,

Manoukias Forones N. Relationship between genetic

polymorphism of CYP1A1 at codon 462 (Ile462Val) in

colorectal cancer. Int J Biol Markers. 2008 Jan-

Mar;23(1):18-23.

127. Jin JQ, Hu YY, Niu YM, Yang GL, Wu YY, Leng WD, et

al. CYP1A1 Ile462Val polymorphism contributes to

colorectal cancer risk: a meta-analysis. World J

Gastroenterol. 2011 Jan 14;17(2):260 -6.

128. Zheng Y, Wang JJ, Sun L, Li HL. Association between

CYP1A1 polymorphism and colorectal cancer risk: a

meta-analysis. Mol Biol Rep. 2011 Jun 28.

129. Yu MW, Chiu YH, Yang SY, Santel la RM, Chern HD, Liaw

YF, et al. Cytochrome P450 1A1 genetic polymorphisms

and risk of hepatocellular carc inoma among chronic

hepatit is B carriers. Br J Cancer. 1999 May;80(3 -4):598-

603.

130. Silvestri L, Sonzogni L, De Silvestri A, Gritt i C, Foti L,

Zavaglia C, et al. CYP enzyme polymorphisms and

susceptibi l ity to HCV-related chronic l iver disease and

liver cancer. Int J Cancer. 2003 Apr 10;104(3):310 -7.

131. Vineis P. The relationship between polymorphisms of

xenobiotic metabolizing enzymes and susceptibil ity to

cancer. Toxicology. 2002 Dec 27;181 -182:457-62.

132. Hefler LA, Tempfer CB, Grimm C, Lebrecht A, Ulbrich E,

Heinze G, et al. Estrogen-metabolizing gene

polymorphisms in the assessment of breast carcinoma

risk and f ibroadenoma risk in Caucasian women. Cancer.

2004 Jul 15;101(2):264-9.

133. Miyoshi Y, Takahashi Y, Egawa C, Noguchi S. Breast

cancer r isk associated with CYP1A1 genetic

polymorphisms in Japanese women. Breast J. 2002 Jul -

Aug;8(4):209-15.

155


134. Huang CS, Chern HD, Chang KJ, Cheng CW, Hsu SM,

Shen CY. Breast cancer r isk associated with genotype

polymorphism of the estrogen-metabolizing genes

CYP17, CYP1A1, and COMT: a multigenic study on

cancer susceptibil ity. Cancer Res. 1999 Oct

1;59(19):4870-5.

135. Masson LF, Sharp L, Cotton SC, Litt le J. Cytochrome P -

450 1A1 gene polymorphisms and risk of breast cancer:

a HuGE review. Am J Epidemiol. 2005 May

15;161(10):901-15.

136. Basham VM, Pharoah PD, Healey CS, Luben RN, Day

NE, Easton DF, et al. Polymorphisms in CYP1A1 and

smoking: no association with breast cancer r isk.

Carcinogenesis. 2001 Nov;22(11):1797-800.

137. Laden F, Ishibe N, Hankinson SE, Wolff MS, Gert ig DM,

Hunter DJ, et al . Polychlorinated biphenyls, cytochrome

P450 1A1, and breast cancer r isk in the Nurses' Health

Study. Cancer Epidemiol Biomarkers Prev. 2002

Dec;11(12):1560-5.

138. Ishibe N, Hankinson SE, Colditz GA, Spiegelman D,

Willett WC, Speizer FE, et al. Cigarette smoking,

cytochrome P450 1A1 polymorphisms, and breast cancer

risk in the Nurses' Health Study. Cancer Res. 1998 Feb

15;58(4):667-71.

139. Miyoshi Y, Ando A, Hasegawa S, Ishitobi M, Yamamura

J, Irahara N, et al. Association of genetic polymorphisms

in CYP19 and CYP1A1 with the oestrogen receptor-

positive breast cancer risk. Eur J Cancer. 2003

Nov;39(17):2531-7.

140. Okobia M, Bunker C, Zmuda J, Kammerer C, Vogel V,

Uche E, et al. Cytochrome P4501A1 genetic

polymorphisms and breast cancer risk in Nigerian

156


women. Breast Cancer Res Treat. 2005 Dec;94(3):285 -

93.

141. Boyapati SM, Shu XO, Gao YT, Cai Q, Jin F, Zheng W.

Polymorphisms in CYP1A1 and breast carcinoma risk in

a population-based case-control study of Chinese

women. Cancer. 2005 Jun 1;103(11):2228-35.

142. Moysich KB, Shields PG, Freudenheim JL, Schisterman

EF, Vena JE, Kostyniak P, et al. Polychlorinated

biphenyls, cytochrome P4501A1 polymorphism, and

postmenopausal breast cancer risk. Cancer Epidemiol

Biomarkers Prev. 1999 Jan;8(1):41-4.

143. Huang CS, Shen CY, Chang KJ, Hsu SM, Chern HD.

Cytochrome P4501A1 polymorphism as a susceptibi l i ty

factor for breast cancer in postmenopausal Chinese

women in Taiwan. Br J Cancer. 1999 Aug;80(11):1838 -

43.

144. Taioli E, Bradlow HL, Garbers SV, Sepkovic DW,

Osborne MP, Trachman J, et al. Role of estradiol

metabolism and CYP1A1 polymorphisms in breast cancer

risk. Cancer Detect Prev. 1999;23(3):232-7.

145. Chacko P, Joseph T, Mathew BS, Rajan B, Pil lai MR.

Role of xenobiotic metabolizing gene polymorphisms in

breast cancer susceptibil ity and treatment outcome.

Mutat Res. 2005 Mar 7;581(1 -2):153-63.

146. da Fonte de Amorim L, Rossini A, Mendonca G, Lotsch

P, de Almeida Simao T, de Moura Gallo C, et al.

CYP1A1, GSTM1, and GSTT1 polymorphisms and breast

cancer risk in Brazil ian women. Cancer Lett. 2002 Jul

26;181(2):179-86.

147. Li Y, Mil l ikan RC, Bell DA, Cui L, Tse CK, Newman B, et

al. Polychlorinated biphenyls, cytochrome P450 1A1

(CYP1A1) polymorphisms, and breast cancer risk among

African American women and white women in North

157


Carolina: a population-based case-control study. Breast

Cancer Res. 2005;7(1):R12-8.

148. Chen C, Huang Y, Li Y, Mao Y, Xie Y. Cytochrome P450

1A1 (CYP1A1) T3801C and A2455G polymorphisms in

breast cancer r isk: a meta-analysis. J Hum Genet.

2007;52(5):423-35.

149. Sergentanis TN, Economopoulos KP. Four

polymorphisms in cytochrome P450 1A1 (CYP1A1) gene

and breast cancer r isk: a meta-analysis. Breast Cancer

Res Treat. 2010 Jul;122(2):459-69.

150. Kraj inovic M, Ghadirian P, Richer C, Sinnett H, Gandini

S, Perret C, et al. Genetic susceptibil ity to breast cancer

in French-Canadians: role of carcinogen-metabolizing

enzymes and gene-environment interact ions. Int J

Cancer. 2001 Apr 15;92(2):220-5.

151. Zhang Y, Wise JP, Holford TR, Xie H, Boyle P, Zahm SH,

et al. Serum polychlorinated biphenyls, cytochrome P -

450 1A1 polymorphisms, and risk of breast cancer in

Connecticut women. Am J Epidemiol. 2004 Dec

15;160(12):1177-83.

152. Sergentanis TN, Economopoulos KP. Erratum to: Four

polymorphisms in cytochrome P450 1A1 (CYP1A1) gene

and breast cancer r isk: a meta-analysis. Breast Cancer

Res Treat. 2010 Jul 30.

153. Suzuki K, Matsui H, Nakazato H, Koike H, Okugi H,

Hasumi M, et al. Association of the genetic polymorphism

in cytochrome P450 (CYP) 1A1 with risk of familial

prostate cancer in a Japanese population: a case -control

study. Cancer Lett. 2003 Jun 10;195(2):177-83.

154. Murata M, Watanabe M, Yamanaka M, Kubota Y, I to H,

Nagao M, et al. Genetic polymorphisms in cytochrome

P450 (CYP) 1A1, CYP1A2, CYP2E1, glutathione S -

transferase (GST) M1 and GSTT1 and susceptibil ity to

158


prostate cancer in the Japanese population. Cancer Lett.

2001 Apr 26;165(2):171-7.

155. Sterl ing KM, Jr., Cutroneo KR. Constitutive and inducible

expression of cytochromes P4501A (CYP1A1 and

CYP1A2) in normal prostate and prostate cancer cel ls. J

Cell Biochem. 2004 Feb 1;91(2):423-9.

156. Chang BL, Zheng SL, Isaacs SD, Turner A, Hawkins GA,

Wiley KE, et al. Polymorphisms in the CYP1A1 gene are

associated with prostate cancer risk. Int J Cancer. 2003

Sep 1;106(3):375-8.

157. Aktas D, Hascicek M, Sozen S, Ozen H, Tuncbilek E.

CYP1A1 and GSTM1 polymorphic genotypes in patients

with prostate cancer in a Turkish population. Cancer

Genet Cytogenet. 2004 Oct 1;154(1):81-5.

158. Li M, Guan TY, Li Y, Na YQ. Polymorphisms of GSTM1

and CYP1A1 genes and their genetic susceptibi l ity to

prostate cancer in Chinese men. Chin Med J (Engl). 2008

Feb 20;121(4):305-8.

159. Sil ig Y, Pinarbasi H, Gunes S, Ayan S, Bagci H,

Cetinkaya O. Polymorphisms of CYP1A1, GSTM1,

GSTT1, and prostate cancer risk in Turkish population.

Cancer Invest. 2006 Feb;24(1):41-5.

160. Lima MM, Jr., Oliveira MN, Granja F, Trindade AC, De

Castro Santos LE, Ward LS. Lack of association of

GSTT1, GSTM1, GSTO1, GSTP1 and CYP1A1

polymorphisms for susceptibi l ity and outcome in Brazil ian

prostate cancer patients. Folia Biol (Praha).

2008;54(3):102-8.

161. Rodrigues IS, Kuasne H, Losi -Guembarovski R, Fuganti

PE, Gregorio EP, Kishima MO, et al. Evaluation of the

inf luence of polymorphic variants CYP1A1*2B,

CYP1B1*2, CYP3A4*1B, GSTM1*0, and GSTT1*0 in

prostate cancer. Urol Oncol. 2010 Sep 28.

159


162. Shaik AP, Jamil K, Das P. CYP1A1 polymorphisms and

risk of prostate cancer: a meta-analysis. Urol J. 2009

Spring;6(2):78-86.

163. Sohda T, Shimizu M, Kamimura S, Okumura M.

Immunohistochemical demonstrat ion of ethanol -inducible

P450 2E1 in rat brain. Alcohol Alcohol Suppl.

1993;1B:69-75.

164. Howard LA, Miksys S, Hoffmann E, Mash D, Tyndale RF.

Brain CYP2E1 is induced by nicot ine and ethanol in rat

and is higher in smokers and alcoholics. Br J Pharmacol.

2003 Apr;138(7):1376-86.

165. Yue J, Khokhar J, Miksys S, Tyndale RF. Differential

induction of ethanol-metabolizing CYP2E1 and nicotine -

metabolizing CYP2B1/2 in rat l iver by chronic nicot ine

treatment and voluntary ethanol intake. Eur J Pharmacol.

2009 May 1;609(1-3):88-95.

166. Seitz HK, Stickel F. Molecular mechanisms of alcohol -

mediated carcinogenesis. Nat Rev Cancer. 2007

Aug;7(8):599-612.

167. Guengerich FP, Kim DH, Iwasaki M. Role of human

cytochrome P-450 IIE1 in the oxidation of many low

molecular weight cancer suspects. Chem Res Toxicol.

1991 Mar-Apr;4(2):168-79.

168. Lewis DF, Bird MG, Parke DV. Molecular modell ing of

CYP2E1 enzymes from rat, mouse and man: an

explanation for species dif ferences in butadiene

metabolism and potential carcinogenicity, and

rationalization of CYP2E substrate specif icity.

Toxicology. 1997 Mar 28;118(2 -3):93-113.

169. Hayashi S, Watanabe J, Kawajiri K. Genetic

polymorphisms in the 5' -f lanking region change

transcriptional regulation of the human cytochrome

P450IIE1 gene. J Biochem. 1991 Oct;110(4):559 -65.

160


170. Chen JM, Ferec C, Cooper DN. A systematic analysis of

disease-associated variants in the 3' regulatory regions

of human protein-coding genes I: general principles and

overview. Hum Genet. 2006 Aug;120(1):1 -21.

171. Matthias C, Jahnke V, Fryer AA, Strange RC. [Inf luence

of glutathione s-transferase and cytochrome p450

polymorphisms on prognosis of head and neck cancer].

Laryngorhinootologie. 2002 Jun;81(6):406-12.

172. Gattas GJ, de Carvalho MB, Siraque MS, Curioni OA,

Kohler P, Eluf -Neto J, et al. Genetic polymorphisms of

CYP1A1, CYP2E1, GSTM1, and GSTT1 associated with

head and neck cancer. Head Neck. 2006 Sep;28(9):

819-26.

173. Ye X, Peng T, Liu T, Su Z, Xiao K, Shang L, et al.

[Association between aldehyde dehydrogenase -

2/cytochrome P450 2E1 genetic polymorphism and habit

of alcohol drinking and the susceptibi l ity of

hepatocellular carcinoma]. Wei Sheng Yan Jiu. 2010

Jan;39(1):42-5.

174. Hata S, Miki Y, Fujishima F, Sato R, Okaue A, Abe K, et

al. Cytochrome 3A and 2E1 in human liver t issue:

Individual variations among normal Japanese subjects.

Life Sci. 2010 Mar 13;86(11-12):393-401.

175. Wang Y, Yang H, Li L, Wang H, Zhang C, Yin G, et al.

Association between CYP2E1 genetic polymorphisms and

lung cancer risk: a meta-analysis. Eur J Cancer. 2010

Mar;46(4):758-64.

176. Klinchid J, Chewaskulyoung B, Saeteng S,

Lertprasertsuke N, Kasinrerk W, Cressey R. Effect of

combined genetic polymorphisms on lung cancer risk in

northern Thai women. Cancer Genet Cytogenet. 2009

Dec;195(2):143-9.

161


177. Kato S, Shields PG, Caporaso NE, Hoover RN, Trump

BF, Sugimura H, et al. Cytochrome P450IIE1 genetic

polymorphisms, racial variat ion, and lung cancer r isk.

Cancer Res. 1992 Dec 1;52(23):6712-5.

178. Tan W, Song N, Wang GQ, Liu Q, Tang HJ, Kadlubar FF,

et al. Impact of genetic polymorphisms in cytochrome

P450 2E1 and glutathione S-transferases M1, T1, and P1

on susceptibi l ity to esophageal cancer among high-risk

individuals in China. Cancer Epidemiol Biomarkers Prev.

2000 Jun;9(6):551-6.

179. Carriere V, Berthou F, Baird S, Belloc C, Beaune P, de

Waziers I. Human cytochrome P450 2E1 (CYP2E1): from

genotype to phenotype. Pharmacogenetics. 1996

Jun;6(3):203-11.

180. Wu X, Shi H, Jiang H, Kemp B, Hong WK, Delclos GL, et

al. Associat ions between cytochrome P4502E1 genotype,

mutagen sensitivity, cigarette smoking and susceptibi l ity

to lung cancer. Carcinogenesis. 1997 May;18(5):967 -73.

181. London SJ, Daly AK, Cooper J, Carpenter CL, Navidi

WC, Ding L, et al. Lung cancer risk in relat ion to the

CYP2E1 Rsa I genetic polymorphism among African -

Americans and Caucasians in Los Angeles County.

Pharmacogenetics. 1996 Apr;6(2):151 -8.

182. Hildesheim A, Chen CJ, Caporaso NE, Cheng YJ, Hoover

RN, Hsu MM, et al. Cytochrome P4502E1 genetic

polymorphisms and risk of nasopharyngeal carcinoma:

results from a case-control study conducted in Taiwan.

Cancer Epidemiol Biomarkers Prev. 1995 Sep;4(6):

607-10.

183. Umeno M, McBride OW, Yang CS, Gelboin HV, Gonzalez

FJ. Human ethanol-inducible P450IIE1: complete gene

sequence, promoter characterization, chromosome

162


mapping, and cDNA-directed expression. Biochemistry.

1988 Dec 13;27(25):9006-13.

184. McBride OW, Umeno M, Gelboin HV, Gonzalez FJ. A Taq

I polymorphism in the human P450IIE1 gene on

chromosome 10 (CYP2E). Nucleic Acids Res. 1987 Dec

10;15(23):10071.

185. Brockmoller J, Cascorbi I, Kerb R, Roots I. Combined

analysis of inherited polymorphisms in arylamine N -

acetyltransferase 2, glutathione S-transferases M1 and

T1, microsomal epoxide hydrolase, and cytochrome P450

enzymes as modulators of bladder cancer risk. Cancer

Res. 1996 Sep 1;56(17):3915-25.

186. Hu Y, Hakkola J, Oscarson M, Ingelman-Sundberg M.

Structural and functional characterizat ion of the 5' -

f lanking region of the rat and human cytochrome P450

2E1 genes: identif ication of a polymorphic repeat in the

human gene. Biochem Biophys Res Commun. 1999 Sep

24;263(2):286-93.

187. McCarver DG, Byun R, Hines RN, Hichme M, Wegenek

W. A genetic polymorphism in the regulatory sequences

of human CYP2E1: associat ion with increased

chlorzoxazone hydroxylation in the presence of obesity

and ethanol intake. Toxicol Appl Pharmacol. 1998

Sep;152(1):276-81.

188. Hu Y, Oscarson M, Johansson I, Yue QY, Dahl ML,

Tabone M, et al. Genetic polymorphism of human

CYP2E1: characterization of two variant al leles. Mol

Pharmacol. 1997 Mar;51(3):370-6.

189. Fairbrother KS, Grove J, de Waziers I, Steimel DT, Day

CP, Crespi CL, et al. Detect ion and characterizat ion of

novel polymorphisms in the CYP2E1 gene.

Pharmacogenetics. 1998 Dec;8(6):543 -52.

163


190. Watanabe J, Hayashi S, Nakachi K, Imai K, Suda Y,

Sekine T, et al. PstI and RsaI RFLPs in complete linkage

disequilibrium at the CYP2E gene. Nucleic Acids Res.

1990 Dec 11;18(23):7194.

191. Persson I, Johansson I, Bergl ing H, Dahl ML, Seidegard

J, Rylander R, et al. Genetic polymorphism of

cytochrome P4502E1 in a Swedish populat ion.

Relat ionship to incidence of lung cancer. FEBS Lett.

1993 Mar 22;319(3):207-11.

192. Itoga S, Nomura F, Makino Y, Tomonaga T, Shimada H,

Ochiai T, et al. Tandem repeat polymorphism of the

CYP2E1 gene: an association study with esophageal

cancer and lung cancer. Alcohol Clin Exp Res. 2002

Aug;26(8 Suppl):15S-9S.

193. Kato S, Shields PG, Caporaso NE, Sugimura H, Trivers

GE, Tucker MA, et al. Analysis of cytochrome P450 2E1

genetic polymorphisms in relat ion to human lung cancer.

Cancer Epidemiol Biomarkers Prev. 1994 Sep;3(6):515 -8.

194. Sugimura H, Hamada GS, Suzuki I, Iwase T, Kiyokawa E,

Kino I, et al. CYP1A1 and CYP2E1 polymorph ism and

lung cancer, case-control study in Rio de Janeiro, Brazi l.

Pharmacogenetics. 1995;5 Spec No:S145-8.

195. Hirvonen A, Husgafvel -Pursiainen K, Antti la S,

Karjalainen A, Vainio H. The human CYP2E1 gene and

lung cancer: DraI and RsaI restriction fragment le ngth

polymorphisms in a Finnish study populat ion.

Carcinogenesis. 1993 Jan;14(1):85-8.

196. Hamada GS, Sugimura H, Suzuki I, Nagura K, Kiyokawa

E, Iwase T, et al. The heme-binding region polymorphism

of cytochrome P450IA1 (CypIA1), rather than the RsaI

polymorphism of IIE1 (CypIIE1), is associated with lung

cancer in Rio de Janeiro. Cancer Epidemiol Biomarkers

Prev. 1995 Jan-Feb;4(1):63-7.

164


197. Watanabe J, Yang JP, Eguchi H, Hayashi S, Imai K,

Nakachi K, et al. An Rsa I polymorphism in the CYP2E1

gene does not affect lung cancer risk in a Japanese

population. Jpn J Cancer Res. 1995 Mar;86(3):245 -8.

198. Sobti RC, Sharma S, Joshi A, Jindal SK, Janmeja A.

Genetic polymorphism of the CYP1A1, CYP2E1, GSTM1

and GSTT1 genes and lung cancer susceptibi l ity in a

north indian population. Mol Cell Biochem. 2004

Nov;266(1-2):1-9.

199. Wu X, Amos CI, Kemp BL, Shi H, Jiang H, Wan Y, et al.

Cytochrome P450 2E1 DraI polymorphisms in lung

cancer in minority populations. Cancer Epidemiol

Biomarkers Prev. 1998 Jan;7(1):13-8.

200. Uematsu F, Kikuchi H, Motomiya M, Abe T, Ishioka C,

Kanamaru R, et al. Human cytochrome P450IIE1 gene:

DraI polymorphism and susceptibil ity to cancer. Tohoku J

Exp Med. 1992 Oct;168(2):113-7.

201. Uematsu F, Ikawa S, Kikuchi H, Sagami I, Kanamaru R,

Abe T, et al. Restriction fragment length polymorphism of

the human CYP2E1 (cytochrome P450IIE1) gene and

susceptibi l ity to lung cancer: possible relevance to low

smoking exposure. Pharmacogenetics. 1994 Apr;4(2):58 -

63.

202. Eom SY, Zhang YW, Kim SH, Choe KH, Lee KY, Park JD,

et al. Inf luence of NQO1, ALDH2, and CYP2E1 genetic

polymorphisms, smoking, and alcohol drinking on the risk

of lung cancer in Koreans. Cancer Causes Control. 2009

Mar;20(2):137-45.

203. Zhan P, Wang J, Zhang Y, Qiu LX, Zhao SF, Qian Q, et

al. CYP2E1 Rsa I/Pst I polymorphism is associated with

lung cancer risk among Asians. Lung Cancer. 2010

Jul;69(1):19-25.

165


204. Lu XM, Zhang YM, Lin RY, Arzi G, Wang X, Zhang YL, et

al. Relat ionship between genetic polymorphisms of

metabolizing enzymes CYP2E1, GSTM1 and Kazakh's

esophageal squamous cell cancer in Xinj iang, China.

World J Gastroenterol. 2005 Jun 28;11(24):3651 -4.

205. Lin D, Tang Y, Peng Q. [Genetic polymorphisms of

cytochrome P450 2E1 and glutathione S-transferase P1

and susceptibi l ity to esophageal cancer]. Zhonghua

Zhong Liu Za Zhi. 1998 Mar;20(2):94-7.

206. Li D, Dandara C, Parker MI. Association of cytochrome

P450 2E1 genetic polymorphisms with squamous cell

carcinoma of the oesophagus. Clin Chem Lab Med.

2005;43(4):370-5.

207. Rossini A, Rapozo DC, Soares Lima SC, Guimaraes DP,

Ferreira MA, Teixeira R, et al. Polymorphisms of GSTP1

and GSTT1, but not of CYP2A6, CYP2E1 or GSTM1,

modify the risk for esophageal cancer in a western

population. Carcinogenesis. 2007 Dec;28(12):2537 -42.

208. Niu Y, Yuan H, Leng W, Pang Y, Gu N, Chen N. CYP2E1

Rsa I/Pst I polymorphism and esophageal cancer risk: a

meta-analysis based on 1,088 cases and 2,238 controls.

Med Oncol. 2011 Mar;28(1):182-7.

209. Kato S, Onda M, Matsukura N, Tokunaga A, Tajir i T, Kim

DY, et al. Cytochrome P4502E1 (CYP2E1) genetic

polymorphism in a case-control study of gastric cancer

and liver disease. Pharmacogenetics. 1995;5 Spec

No:S141-4.

210. Park GT, Lee OY, Kwon SJ, Lee CG, Yoon BC, Hahm JS,

et al. Analysis of CYP2E1 polymorphism for the

determination of genetic susceptibi l ity to gastric cancer

in Koreans. J Gastroenterol Hepatol. 2003 Nov;

18(11):1257-63.

166


211. Cai L, Zheng ZL, Zhang ZF. Cytochrome p450 2E1

polymorphisms and the risk of gastric cardia cancer.

World J Gastroenterol. 2005 Mar 28;11(12):1867 -71.

212. Wu MS, Chen CJ, Lin MT, Wang HP, Shun CT, Sheu JC,

et al. Genetic polymorphisms of cytochrome p450 2E1,

glutathione S-transferase M1 and T1, and susceptibi l ity

to gastric carcinoma in Taiwan. Int J Colorectal Dis. 2002

Sep;17(5):338-43.

213. Colombo J, Rossit AR, Caetano A, Borim AA, Wornrath

D, Silva AE. GSTT1, GSTM1 and CYP2E1 genetic

polymorphisms in gastric cancer and chronic gastrit is in

a Brazil ian populat ion. World J Gastroenterol. 2004 May

1;10(9):1240-5.

214. Agudo A, Sala N, Pera G, Capella G, Berenguer A,

Garcia N, et al. No association between polymorphisms

in CYP2E1, GSTM1, NAT1, NAT2 and the risk of gastric

adenocarcinoma in the European prospective

investigation into cancer and nutrit ion. Cancer Epidemiol

Biomarkers Prev. 2006 May;15(5):1043-5.

215. Masuda G, Tokunaga A, Shirakawa T, Togashi A, Kiyama

T, Kato S, et al. Helicobacter pylori infection, but not

genetic polymorphism of CYP2E1, is highly prevalent in

gastric cancer patients younger than 40 years. Gastric

Cancer. 2007;10(2):98-103.

216. van der Logt EM, Bergevoet SM, Roelofs HM, Te

Morsche RH, Dijk Y, Wobbes T, et al. Role of epoxide

hydrolase, NAD(P)H:quinone oxidoreductase, cytochrome

P450 2E1 or alcohol dehydrogenase genotypes in

susceptibi l ity to colorectal cancer. Mutat Res. 2006 Jan

29;593(1-2):39-49.

217. Gao CM, Takezaki T, Wu JZ, Chen MB, Liu YT, Ding JH,

et al. CYP2E1 Rsa I polymorphism impacts on risk of

colorectal cancer association with smoking and alcohol

167


drinking. World J Gastroenterol. 2007 Nov

21;13(43):5725-30.

218. Morita M, Le Marchand L, Kono S, Yin G, Toyomura K,

Nagano J, et al. Genetic polymorphisms of CYP2E1 and

risk of colorectal cancer: the Fukuoka Colorectal Cancer

Study. Cancer Epidemiol Biomarkers Prev. 2009

Jan;18(1):235-41.

219. Yang H, Zhou Y, Zhou Z, Liu J, Yuan X, Matsuo K, et al.

A novel polymorphism rs1329149 of CYP2E1 and a

known polymorphism rs671 of ALDH2 of alcohol

metabolizing enzymes are associated with colorectal

cancer in a southwestern Chinese population. Cancer

Epidemiol Biomarkers Prev. 2009 Sep;18(9):2522 -7.

220. Zhou GW, Hu J, Li Q. CYP2E1 PstI/RsaI polymorphism

and colorectal cancer risk: a meta-analysis. World J

Gastroenterol. 2010 Jun 21;16(23):2949-53.

221. Yu MW, Gladek-Yarborough A, Chiamprasert S, Santella

RM, Liaw YF, Chen CJ. Cytochrome P450 2E1 and

glutathione S-transferase M1 polymorphisms and

susceptibi l ity to hepatocellular carcinoma.

Gastroenterology. 1995 Oct;109(4):1266-73.

222. Lee HS, Yoon JH, Kamimura S, Iwata K, Watanabe H,

Kim CY. Lack of association of cytochrome P450 2E1

genetic polymorphisms with the risk of human

hepatocellular carcinoma. Int J Cancer. 1997 May

29;71(5):737-40.

223. Munaka M, Kohshi K, Kawamoto T, Takasawa S, Nagata

N, Itoh H, et al. Genetic polymorphisms of tobacco - and

alcohol-related metabolizing enzymes and the risk of

hepatocellular carcinoma. J Cancer Res Clin Oncol. 2003

Jun;129(6):355-60.

224. Kapucuoglu N, Coban T, Raunio H, Pelkonen O, Edwards

RJ, Boobis AR, et al. Immunohistochemical

168


demonstration of the expression of CYP2E1 in human

breast tumour and non-tumour tissues. Cancer Lett. 2003

Jul 10;196(2):153-9.

225. Choi JY, Abel J, Neuhaus T, Ko Y, Harth V, Hamajima N,

et al. Role of alcohol and genetic polymorphisms of

CYP2E1 and ALDH2 in breast cancer development.

Pharmacogenetics. 2003 Feb;13(2):67 -72.

226. Khedhaier A, Hassen E, Bouaouina N, Gabbouj S, Ahmed

SB, Chouchane L. Implicat ion of Xenobiotic Metabo lizing

Enzyme gene (CYP2E1, CYP2C19, CYP2D6, mEH and

NAT2) polymorphisms in breast carcinoma. BMC Cancer.

2008;8:109.

227. Ferreira PM, Medeiros R, Vasconcelos A, Costa S, Pinto

D, Morais A, et al. Associat ion between CYP2E1

polymorphisms and susceptibil ity to prostate cancer. Eur

J Cancer Prev. 2003 Jun;12(3):205-11.

228. Yang J, Wu HF, Zhang W, Gu M, Hua LX, Sui YG, et al.

Polymorphisms of metabolic enzyme genes, l iving habits

and prostate cancer susceptibil ity. Front Biosci.

2006;11:2052-60.

229. Yang J, Qian LX, Wu HF, Xu ZQ, Sui YG, Wang XR, et

al. Genetic polymorphisms in the cytochrome P450 1A1

and 2E1 genes, smoking, drinking and prostate cancer

susceptibi l ity: a case-control study in a Han nationality

population in Southern China. Int J Urol. 2006

Jun;13(6):773-80.

230. Yang J, Gu M, Song NH, Feng NH, Hua LX, Ju XB, et al.

[Correlat ion of prostate cancer susceptibi l ity with genetic

polymorphism of cytochrome P450 2E1, smoking and

drinking: a case-control study in the population of

Nanjing area]. Zhonghua Nan Ke Xue. 2009 Jan;15(1):

7-11.

169


231. Decker M, Arand M, Cronin A. Mammalian epoxide

hydrolases in xenobiotic metabolism and signall ing. Arch

Toxicol. 2009 Apr;83(4):297-318.

232. Coller JK, Fritz P, Zanger UM, Siegle I, Eichelbaum M,

Kroemer HK, et al. Distribut ion of microsomal epoxide

hydrolase in humans: an immunohistochemical study in

normal t issues, and benign and malignant tumours.

Histochem J. 2001 Jun;33(6):329-36.

233. Beetham JK, Grant D, Arand M, Garbarino J, Kiyosue T,

Pinot F, et al. Gene evolution of epoxide hydrolases and

recommended nomenclature. DNA Cell Biol. 1995

Jan;14(1):61-71.

234. Taura Ki K, Yamada H, Naito E, Ariyoshi N, Mori Ma MA,

Oguri K. Activation of microsomal epoxide hydrolase by

interaction with cytochromes P450: kinetic analysis of

the association and substrate-specif ic act ivat ion of

epoxide hydrolase function. Arch Biochem Biophys. 2002

Jun 15;402(2):275-80.

235. Taura KI, Yamada H, Hagino Y, Ishii Y, Mori MA, Oguri

K. Interaction between cytochrome P450 and other drug -

metabolizing enzymes: evidence for an associat ion of

CYP1A1 with microsomal epoxide hydrolase and UDP -

glucuronosyltransferase. Biochem Biophys Res Commun.

2000 Jul 14;273(3):1048-52.

236. Shou M, Gonzalez FJ, Gelboin HV. Stereoselective

epoxidation and hydration at the K-region of polycycl ic

aromatic hydrocarbons by cDNA-expressed cytochromes

P450 1A1, 1A2, and epoxide hydrolase. Biochemistry.

1996 Dec 10;35(49):15807-13.

237. Hartsf ield JK, Jr., Sutclif fe MJ, Everett ET, Hassett C,

Omiecinski CJ, Saari JA. Assignment1 of microsomal

epoxide hydrolase (EPHX1) to human chromosome

170


1q42.1 by in situ hybridizat ion. Cytogenet Cell Genet.

1998;83(1-2):44-5.

238. Hassett C, Robinson KB, Beck NB, Omiecinski CJ. The

human microsomal epoxide hydrolase gene (EPHX1):

complete nucleotide sequence and structural

characterization. Genomics. 1994 Sep 15;23(2):433 -42.

239. Skoda RC, Demierre A, McBride OW, Gonzalez FJ,

Meyer UA. Human microsomal xenobiotic epoxide

hydrolase. Complementary DNA sequence,

complementary DNA-directed expression in COS-1 cells,

and chromosomal localizat ion. J Biol Chem. 1988 Jan

25;263(3):1549-54.

240. Gaedigk A, Leeder JS, Grant DM. Tissue -specif ic

expression and alternative splicing of human microsomal

epoxide hydrolase. DNA Cell Biol. 1997

Nov;16(11):1257-66.

241. !!! INVALID CITATION !!!

242. Omiecinski CJ, Aicher L, Holubkov R, Checkoway H.

Human peripheral lymphocytes as indicators of

microsomal epoxide hydrolase act ivity in l iver and lung.

Pharmacogenetics. 1993 Jun;3(3):150 -8.

243. Zhu QS, Qian B, Levy D. Regulation of human

microsomal epoxide hydrolase gene (EPHX1) expression

by the transcription factor GATA-4. Biochim Biophys

Acta. 2004 Feb 20;1676(3):251-60.

244. Zhu QS, Qian B, Levy D. CCAAT/enhancer -binding

protein alpha (C/EBPalpha) act ivates transcription of the

human microsomal epoxide hydrolase gene (EPHX1)

through the interaction with DNA-bound NF-Y. J Biol

Chem. 2004 Jul 16;279(29):29902-10.

245. Nebert DW, Gonzalez FJ. P450 genes: structure,

evolution, and regulat ion. Annu Rev Biochem.

1987;56:945-93.

171


246. Hassett C, Aicher L, Sidhu JS, Omiecinski CJ. Human

microsomal epoxide hydrolase: genetic polymorphism

and functional expression in vitro of amino acid variants.

Hum Mol Genet. 1994 Mar;3(3):421-8.

247. Baxter SW, Choong DY, Campbell IG. Microsomal

epoxide hydrolase polymorphism and susceptibi l ity to

ovarian cancer. Cancer Lett. 2002 Mar 8;177(1):75 -81.

248. Yoshikawa M, Hiyama K, Ishioka S, Maeda H, Maeda A,

Yamakido M. Microsomal epoxide hydrolase genotypes

and chronic obstructive pulmonary disease in Japanese.

Int J Mol Med. 2000 Jan;5(1):49-53.

249. Benhamou S, Reinikainen M, Bouchardy C, Dayer P,

Hirvonen A. Association between lung cancer and

microsomal epoxide hydrolase genotypes. Cancer Res.

1998 Dec 1;58(23):5291-3.

250. Smith CA, Harrison DJ. Association between

polymorphism in gene for microsomal epoxide hydrolase

and susceptibi l ity to emphysema. Lancet. 1997 Aug

30;350(9078):630-3.

251. Zhou W, Liu G, Thurston SW, Xu LL, Miller DP, Wain JC,

et al. Genetic polymorphisms in N-acetyltransferase-2

and microsomal epoxide hydrolase, cumulative cigarette

smoking, and lung cancer. Cancer Epidemiol Biomarkers

Prev. 2002 Jan;11(1):15-21.

252. Cajas-Salazar N, Au WW, Zwischenberger JB, Sierra -

Torres CH, Salama SA, Alpard SK, et al. Effect of

epoxide hydrolase polymorphisms on chromosome

aberrat ions and risk for lung cancer. Cancer Genet

Cytogenet. 2003 Sep;145(2):97-102.

253. Gsur A, Zidek T, Schnattinger K, Feik E, Haidinger G,

Hollaus P, et al. Associat ion of microsomal epoxide

hydrolase polymorphisms and lung cancer risk. Br J

Cancer. 2003 Aug 18;89(4):702-6.

172


254. Graziano C, Comin CE, Crisci C, Novell i L, Polit i L,

Messerini L, et al. Functional polymorphisms of the

microsomal epoxide hydrolase gene: a reappraisal on a

early-onset lung cancer patients series. Lung Cancer.

2009 Feb;63(2):187-93.

255. Park JY, Schantz SP, Lazarus P. Epoxide hydrolase

genotype and orolaryngeal cancer risk: interact ion with

GSTM1 genotype. Oral Oncol. 2003 Jul;39(5):483 -90.

256. Jourenkova-Mironova N, Mitrunen K, Bouchardy C, Dayer

P, Benhamou S, Hirvonen A. High -activity microsomal

epoxide hydrolase genotypes and the risk of oral,

pharynx, and larynx cancers. Cancer Res. 2000 Feb

1;60(3):534-6.

257. Jain M, Ti lak AR, Upadhyay R, Kumar A, Mittal B.

Microsomal epoxide hydrolase (EPHX1), slow (exon 3,

113His) and fast (exon 4, 139Arg) alleles confer

susceptibi l ity to squamous cell esophageal cancer.

Toxicol Appl Pharmacol. 2008 Jul 15;230(2):247 -51.

258. Silveira Vda S, Canalle R, Scrideli CA, Queiroz RG, Tone

LG. Role of the CYP2D6, EPHX1, MPO, and NQO1 genes

in the susceptibi l ity to acute lymphoblastic leukemia in

Brazil ian children. Environ Mol Mutagen. 2010

Jan;51(1):48-56.

259. Lee WJ, Brennan P, Boffetta P, London SJ, Benhamou S,

Rannug A, et al. Microsomal epoxide hydrolase

polymorphisms and lung cancer r isk: a quantitat ive

review. Biomarkers. 2002 May-Jun;7(3):230-41.

260. Erkisi Z, Yaylim-Eraltan I, Turna A, Gormus U, Camlica

H, Isbir T. Polymorphisms in the microsomal epoxide

hydrolase gene: role in lung cancer susceptibil ity and

prognosis. Tumori. 2010 Sep-Oct;96(5):756-63.

261. Sun XW, Ma YY, Wang B. [The interact ion between

microsomal epoxide hydrolase polymorphisms and indoor

173


pollut ion in non small cel l lung cancer]. Zhonghua Yu

Fang Yi Xue Za Zhi. 2007 Jun;41 Suppl:30 -4.

262. Habalova V, Salagovic J, Kalina I, Stubna J. Combined

analysis of polymorphisms in glutathione S-transferase

M1 and microsomal epoxide hydrolase in lung cancer

patients. Neoplasma. 2004;51(5):352 -7.

263. Kiyohara C, Yoshimasu K, Takayama K, Nakanishi Y.

EPHX1 polymorphisms and the risk of lung cancer: a

HuGE review. Epidemiology. 2006 Jan;17(1):89 -99.

264. Li X, Hu Z, Qu X, Zhu J, Li L, Ring BZ, et al. Putat ive

EPHX1 enzyme activity is related with risk of lung and

upper aerodigestive tract cancers: a comprehensive

meta-analysis. PLoS One. 2011;6(3):e14749.

265. Casson AG, Zheng Z, Chiasson D, MacDonald K, Riddell

DC, Guernsey JR, et al. Associations between genetic

polymorphisms of Phase I and II metabolizing enzymes,

p53 and susceptibil ity to esophageal adenocarcinoma.

Cancer Detect Prev. 2003;27(2):139 -46.

266. Zhang JH, Jin X, Li Y, Wang R, Guo W, Wang N, et al.

Epoxide hydrolase Tyr113His polymorphism is not

associated with susceptibil ity to esophageal squamous

cell carcinoma in population of North China. World J

Gastroenterol. 2003 Dec;9(12):2654-7.

267. Lin YC, Wu DC, Lee JM, Hsu HK, Kao EL, Yang CH, et

al. The associat ion between microsomal epoxide

hydrolase genotypes and esophageal squamous-cell-

carcinoma in Taiwan: interact ion between areca chewing

and smoking. Cancer Lett. 2006 Jun 18;237(2):281 -8.

268. Liu CY, Wu MC, Chen F, Ter -Minassian M, Asomaning K,

Zhai R, et al. A Large-scale genetic association study of

esophageal adenocarcinoma risk. Carcinogenesis. 2010

Jul;31(7):1259-63.

174


269. Ihsan R, Chattopadhyay I, Phukan R, Mishra AK,

Purkayastha J, Sharma J, et al. Role of epoxide

hydrolase 1 gene polymorphisms in esophageal cancer in

a high-risk area in India. J Gastroenterol Hepatol. 2010

Aug;25(8):1456-62.

270. Agudo A, Sala N, Pera G, Capella G, Berenguer A,

Garcia N, et al. Polymorphisms in metabolic genes

related to tobacco smoke and the risk of gastric cancer

in the European prospective investigation into cancer

and nutrit ion. Cancer Epidemiol Biomarkers Prev. 2006

Dec;15(12):2427-34.

271. Boccia S, Sayed-Tabatabaei FA, Persiani R, Gianfagna

F, Rausei S, Arzani D, et al. Polymorphisms in metabolic

genes, their combination and interaction with tobacco

smoke and alcohol consumption and risk of gastric

cancer: a case-control study in an Italian population.

BMC Cancer. 2007;7:206.

272. Ikeda S, Sasazuki S, Natsukawa S, Shaura K, Koizumi Y,

Kasuga Y, et al. Screening of 214 single nucleotide

polymorphisms in 44 candidate cancer susceptibi l ity

genes: a case-control study on gastric and colorectal

cancers in the Japanese population. Am J Gastroenterol.

2008 Jun;103(6):1476-87.

273. Tranah GJ, Giovannucci E, Ma J, Fuchs C, Hankinson

SE, Hunter DJ. Epoxide hydrolase polymorphisms,

cigarette smoking and risk of colorectal adenoma in the

Nurses' Health Study and the Health Professionals

Follow-up Study. Carcinogenesis. 2004 Jul;25(7):1211 -8.

274. Huang WY, Chatterjee N, Chanock S, Dean M, Yeager M,

Schoen RE, et al. Microsomal epoxide hydrolase

polymorphisms and risk for advanced colorectal

adenoma. Cancer Epidemiol Biomarkers Prev. 2005

Jan;14(1):152-7.

175


275. Mitrou PN, Watson MA, Loktionov AS, Cardwell C,

Gunter MJ, Atkin WS, et al. Role of NQO1C609T and

EPHX1 gene polymorphisms in the association of

smoking and alcohol with sporadic distal colorectal

adenomas: results from the UKFSS Study.

Carcinogenesis. 2007 Apr;28(4):875 -82.

276. Kiss I, Orsos Z, Gombos K, Bogner B, Csejtei A, Tibold

A, et al. Association between al lel ic polymorphisms of

metabolizing enzymes (CYP 1A1, CYP 1A2, CYP 2E1,

mEH) and occurrence of colorectal cancer in Hungary.

Anticancer Res. 2007 Jul -Aug;27(4C):2931-7.

277. Skjelbred CF, Saebo M, Hjartaker A, Grotmol T,

Hansteen IL, Tveit KM, et al. Meat, vegetables and

genetic polymorphisms and the risk of colorectal

carcinomas and adenomas. BMC Cancer. 2007;7:228.

278. Raimondi S, Botteri E, Iodice S, Lowenfels AB,

Maisonneuve P. Gene-smoking interaction on colorectal

adenoma and cancer r isk: review and meta -analysis.

Mutat Res. 2009 Nov 2;670(1-2):6-14.

279. Pande M, Amos CI, Eng C, Frazier ML. Interact ions

between cigarette smoking and selected polymorphisms

in xenobiot ic metabolizing enzymes in risk for colorectal

cancer: A case-only analysis. Mol Carcinog. 2010

Nov;49(11):974-80.

280. Burnett-Hartman AN, Newcomb PA, Mandelson MT,

Adams SV, Wernli KJ, Shadman M, et al. Colorectal

polyp type and the associat ion with charred meat

consumption, smoking, and microsomal epoxide

hydrolase polymorphisms. Nutr Cancer. 2011

May;63(4):583-92.

281. McGlynn KA, Rosvold EA, Lustbader ED, Hu Y, Clapper

ML, Zhou T, et al. Susceptibil ity to hepatocellular

carcinoma is associated with genetic variat ion in the

176


enzymatic detoxif ication of af latoxin B1. Proc Natl Acad

Sci U S A. 1995 Mar 14;92(6):2384-7.

282. Tiemersma EW, Omer RE, Bunschoten A, van't Veer P,

Kok FJ, Idris MO, et al. Role of genetic polymorphism of

glutathione-S-transferase T1 and microsomal epoxide

hydrolase in af latoxin-associated hepatocellular

carcinoma. Cancer Epidemiol Biomarkers Prev. 2001

Jul;10(7):785-91.

283. Kelly EJ, Erickson KE, Sengstag C, Eaton DL.

Expression of human microsomal epoxide hydrolase in

Saccharomyces cerevisiae reveals a functional role in

af latoxin B1 detoxif icat ion. Toxicol Sci. 2002

Jan;65(1):35-42.

284. Sonzogni L, Si lvestri L, De Silvestri A, Gritt i C, Foti L,

Zavaglia C, et al. Polymorphisms of microsomal epoxide

hydrolase gene and severity of HCV-related l iver

disease. Hepatology. 2002 Jul;36(1):195-201.

285. Kiran M, Chawla YK, Kaur J. Glutathione-S-transferase

and microsomal epoxide hydrolase polymorphism and

viral-related hepatocellular carcinoma risk in India. DNA

Cell Biol. 2008 Dec;27(12):687-94.

286. Kiran M, Chawla YK, Jain M, Kaur J. Haplotypes of

microsomal epoxide hydrolase and x-ray cross-

complementing group 1 genes in Indian hepatocellular

carcinoma patients. DNA Cell Biol. 2009 Nov;28(11):

573-7.

287. Sarmanova J, Susova S, Gut I, Mrhalova M, Kodet R,

Adamek J, et al. Breast cancer: role of polymorphisms in

biotransformation enzymes. Eur J Hum Genet. 2004

Oct;12(10):848-54.

288. Spurdle AB, Chang JH, Byrnes GB, Chen X, Dite GS,

McCredie MR, et al. A systematic approach to analysing

gene-gene interactions: polymorphisms at the

177


microsomal epoxide hydrolase EPHX and glutathione S -

transferase GSTM1, GSTT1, and GSTP1 loci and breast

cancer risk. Cancer Epidemiol Biomarkers Prev. 2007

Apr;16(4):769-74.

289. Justenhoven C, Hamann U, Schubert F, Zapatka M, Pierl

CB, Rabstein S, et al. Breast cancer: a candidate gene

approach across the estrogen metabolic pathway. Breast

Cancer Res Treat. 2008 Mar;108(1):137-49.

290. Sangrajrang S, Sato Y, Sakamoto H, Ohnami S, Laird

NM, Khuhaprema T, et al. Genetic polymorphisms of

estrogen metabolizing enzyme and breast cancer risk in

Thai women. Int J Cancer. 2009 Aug 15;125(4):837 -43.

291. Figer A, Friedman T, Manguoglu AE, Flex D, Vaz ina A,

Novikov I, et al. Analysis of polymorphic patterns in

candidate genes in Israeli patients with prostate cancer.

Isr Med Assoc J. 2003 Oct;5(10):741-5.

292. Nock NL, Liu X, Cicek MS, Li L, Macarie F, Rybicki BA,

et al. Polymorphisms in polycycl ic aromatic hydrocarbon

metabolism and conjugation genes, interactions with

smoking and prostate cancer risk. Cancer Epidemiol

Biomarkers Prev. 2006 Apr;15(4):756-61.

293. Nock NL, Tang D, Rundle A, Neslund-Dudas C, Savera

AT, Bock CH, et al. Associat ions between smoking,

polymorphisms in polycycl ic aromatic hydrocarbon (PAH)

metabolism and conjugation genes and PAH-DNA

adducts in prostate tumors dif fer by race. Cancer

Epidemiol Biomarkers Prev. 2007 Jun;16(6):1236 -45.

294. Figueroa JD, Malats N, Garcia -Closas M, Real FX,

Silverman D, Kogevinas M, et al. Bladder cancer r isk and

genetic variat ion in AKR1C3 and other metabolizing

genes. Carcinogenesis. 2008 Oct;29(10):1955-62.

295. Riddle B, Jencks WP. Acetyl -coenzyme A: arylamine N-

acetyltransferase. Role of the acetyl -enzyme

178


intermediate and the effects of substituents on the rate. J

Biol Chem. 1971 May 25;246(10):3250-8.

296. Butcher NJ, Boukouvala S, Sim E, Minchin RF.

Pharmacogenetics of the arylamine N-acetyltransferases.

Pharmacogenomics J. 2002;2(1):30-42.

297. Grant DM, Goodfellow GH, Sugamori K, Durette K.

Pharmacogenetics of the human arylamine N-

acetyltransferases. Pharmacology. 2000 Sep;61(3):

204-11.

298. Hickman D, Risch A, Camilleri JP, Sim E. Genotyping

human polymorphic arylamine N-acetyltransferase:

identif icat ion of new slow allotypic variants.

Pharmacogenetics. 1992 Oct;2(5):217 -26.

299. Dorne JL, Walton K, Renwick AG. Polymorphic CYP2C19

and N-acetylat ion: human variabil ity in kinetics and

pathway-related uncertainty factors. Food Chem Toxicol.

2003 Feb;41(2):225-45.

300. Evans DA. N-acetyltransferase. Pharmacol Ther.

1989;42(2):157-234.

301. Meyer UA, Zanger UM. Molecular mechanisms of genetic

polymorphisms of drug metabolism. Annu Rev Pharmacol

Toxicol. 1997;37:269-96.

302. Delomenie C, Sica L, Grant DM, Krishnamoorthy R,

Dupret JM. Genotyping of the polymorphic N-

acetyltransferase (NAT2*) gene locus in two native

African populat ions. Pharmacogenetics. 1996

Apr;6(2):177-85.

303. Fret land AJ, Leff MA, Doll MA, Hein DW. Functional

characterization of human N-acetyltransferase 2 (NAT2)

single nucleotide polymorphisms. Pharmacogenetics.

2001 Apr;11(3):207-15.

304. Hein DW, Fretland AJ, Doll MA. Effects of single

nucleotide polymorphisms in human N-acetyltransferase

179


2 on metabolic act ivat ion (O-acetylation) of heterocyclic

amine carcinogens. Int J Cancer. 2006 Sep

1;119(5):1208-11.

305. Zang Y, Doll MA, Zhao S, States JC, Hein DW.

Functional characterizat ion of single -nucleotide

polymorphisms and haplotypes of human N-

acetyltransferase 2. Carcinogenesis. 2007

Aug;28(8):1665-71.

306. Agundez JA, Olivera M, Martinez C, Ladero JM, Benitez

J. Identif icat ion and prevalence study of 17 allelic

variants of the human NAT2 gene in a white populat ion.

Pharmacogenetics. 1996 Oct;6(5):423 -8.

307. Cascorbi I, Drakoulis N, Brockmoller J, Maurer A,

Sperl ing K, Roots I. Arylamine N-acetyltransferase

(NAT2) mutations and their al lel ic l inkage in unrelated

Caucasian individuals: correlat ion with phenotypic

activity. Am J Hum Genet. 1995 Sep;57(3):581 -92.

308. Dandara C, Masimirembwa CM, Magimba A, Kaaya S,

Sayi J, Sommers DK, et al. Arylamine N-

acetyltransferase (NAT2) genotypes in Africans: the

identif icat ion of a new allele with nucleotide changes

481C>T and 590G>A. Pharmacogenetics. 2003

Jan;13(1):55-8.

309. Burgess EJ, Trafford JA. Acetylator phenotype in

patients with lung carcinoma--a negative report. Eur J

Respir Dis. 1985 Jul;67(1):17-9.

310. Roots I, Drakoulis N, Ploch M, Heinemeyer G,

Loddenkemper R, Minks T, et al. Debrisoquine

hydroxylat ion phenotype, acetylation phenotype, and

ABO blood groups as genetic host factors of lung cancer

risk. Klin Wochenschr. 1988;66 Suppl 11:87-97.

180


311. Phil ip PA, Fitzgerald DL, Cartwright RA, Peake MD,

Rogers HJ. Polymorphic N-acetylat ion capacity in lung

cancer. Carcinogenesis. 1988 Mar;9(3):491-3.

312. Sorensen M, Autrup H, Tjonneland A, Overvad K,

Raaschou-Nielsen O. Genetic polymorphisms in CYP1B1,

GSTA1, NQO1 and NAT2 and the risk of lung cancer.

Cancer Lett. 2005 Apr 28;221(2):185-90.

313. Bouchardy C, Mitrunen K, Wikman H, Husgafvel -

Pursiainen K, Dayer P, Benhamou S, et al. N -

acetyltransferase NAT1 and NAT2 genotypes and lung

cancer risk. Pharmacogenetics. 1998 Aug;8(4):291 -8.

314. Mart inez C, Agundez JA, Olivera M, Mart in R, Ladero JM,

Benitez J. Lung cancer and mutations at the polymorphic

NAT2 gene locus. Pharmacogenetics. 1995 Aug;5(4):

207-14.

315. Belogubova EV, Kuligina E, Togo AV, Karpova MB,

Ulibina JM, Shutkin VA, et al. 'Comparison of extremes'

approach provides evidence against the modifying role of

NAT2 polymorphism in lung cancer susceptibil ity. Cancer

Lett. 2005 Apr 28;221(2):177-83.

316. Chiou HL, Wu MF, Chien WP, Cheng YW, Wong RH,

Chen CY, et al. NAT2 fast acetylator genotype is

associated with an increased risk of lung cancer among

never-smoking women in Taiwan. Cancer Lett. 2005 Jun

1;223(1):93-101.

317. Habalova V, Salagovic J, Kalina I, Stubna J. A pilot study

testing the genetic polymorphism of N-acetyltransferase

2 as a risk factor in lung cancer. Neoplasma.

2005;52(5):364-8.

318. Osawa Y, Osawa KK, Miyaishi A, Higuchi M, Tsutou A,

Matsumura S, et al. NAT2 and CYP1A2 polymorphisms

and lung cancer risk in relat ion to smoking status. Asian

Pac J Cancer Prev. 2007 Jan-Mar;8(1):103-8.

181


319. Cui D, Wang Z, Zhao E, Ma J, Lu W. NAT2 polymorphism

and lung cancer risk: a meta -analysis. Lung Cancer.

2011 Aug;73(2):153-7.

320. Shibuta J, Eto T, Kataoka A, Inoue H, Ueo H, Suzuki T,

et al. Genetic polymorphism of N-acetyltransferase 2 in

patients with esophageal cancer. Am J Gastroenterol.

2001 Dec;96(12):3419-24.

321. Jain M, Kumar S, Lal P, Tiwari A, Ghoshal UC, Mittal B.

Association of genetic polymorphisms of N-

acetyltransferase 2 and susceptibil ity to esophageal

cancer in north Indian population. Cancer Invest. 2007

Aug;25(5):340-6.

322. Akbari MR, Malekzadeh R, Shakeri R, Nasrol lahzadeh D,

Foumani M, Sun Y, et al. Candidate gene association

study of esophageal squamous cell carcinoma in a high -

risk region in Iran. Cancer Res. 2009 Oct

15;69(20):7994-8000.

323. Malik MA, Upadhyay R, Modi DR, Zargar SA, Mittal B.

Association of NAT2 gene polymorphisms with

susceptibi l ity to esophageal and gastric cancers in the

Kashmir Valley. Arch Med Res. 2009 Jul;40(5):416 -23.

324. Ladero JM, Agundez JA, Olivera M, Lozano L,

Rodriguez-Lescure A, Diaz-Rubio M, et al. N-

acetyltransferase 2 single -nucleotide polymorphisms and

risk of gastric carcinoma. Eur J Clin Pharmacol. 2002

May;58(2):115-8.

325. Hong SH, Kim JW, Kim HG, Park IK, Ryoo JW, Lee CH,

et al. [Glutathione S-transferases (GSTM1, GSTT1 and

GSTP1) and N-acetyltransferase 2 polymorphisms and

the risk of gastric cancer]. J Prev Med Public Health.

2006 Mar;39(2):135-40.

326. Boissy RJ, Watson MA, Umbach DM, Deakin M, Elder J,

Strange RC, et al. A pilot study investigating the role of

182


NAT1 and NAT2 polymorphisms in gastric

adenocarcinoma. Int J Cancer. 2000 Aug 15;87(4):507 -

11.

327. Lan Q, Rothman N, Chow WH, Lissowska J, Doll MA,

Xiao GH, et al. No apparent associat ion between NAT1

and NAT2 genotypes and risk of stomach cancer. Cancer

Epidemiol Biomarkers Prev. 2003 Apr;12(4):384 -6.

328. Katoh T, Boissy R, Nagata N, Kitagawa K, Kuroda Y, Itoh

H, et al. Inherited polymorphism in the N -

acetyltransferase 1 (NAT1) and 2 (NAT2) genes and

susceptibi l ity to gastric and colorectal adenocarcinoma.

Int J Cancer. 2000 Jan 1;85(1):46-9.

329. Kobayashi M, Otani T, Iwasaki M, Natsukawa S, Shaura

K, Koizumi Y, et al. Association between dietary

heterocyclic amine levels, genetic polymorphisms of

NAT2, CYP1A1, and CYP1A2 and risk of stomach

cancer: a hospital -based case-control study in Japan.

Gastric Cancer. 2009;12(4):198-205.

330. Al-Moundhri MS, Al-Kindi M, Al-Nabhani M, Al-Bahrani B,

Burney IA, Al-Madhani A, et al. NAT2 polymorphism in

Omani gastric cancer patients-risk predisposit ion and

clinicopathological associations. World J Gastroenterol.

2007 May 21;13(19):2697-702.

331. Zhang YW, Eom SY, Kim YD, Song YJ, Yun HY, Park JS,

et al. Effects of dietary factors and the NAT2 acetylator

status on gastric cancer in Koreans. Int J Cancer. 2009

Jul 1;125(1):139-45.

332. Zhong X, Hui C, Xiao-Ling W, Yan L, Na L. NAT2

polymorphism and gastric cancer susceptibi l ity: a meta -

analysis. Arch Med Res. 2010 May;41(4):275-80.

333. Lang NP, Chu DZ, Hunter CF, Kendall DC, Flammang TJ,

Kadlubar FF. Role of aromatic amine acetyltransferase in

183


human colorectal cancer. Arch Surg. 1986 Nov; 121(11):

1259-61.

334. Gil JP, Lechner MC. Increased frequency of wild -type

arylamine-N-acetyltransferase allele NAT2*4

homozygotes in Portuguese patients with colorectal

cancer. Carcinogenesis. 1998 Jan;19(1):37 -41.

335. I lett KF, David BM, Detchon P, Castleden WM, Kwa R.

Acetylat ion phenotype in colorectal carcinoma. Cancer

Res. 1987 Mar 1;47(5):1466-9.

336. Frazier ML, O'Donnell FT, Kong S, Gu X, Campos I,

Luthra R, et al. Age-associated risk of cancer among

individuals with N-acetyltransferase 2 (NAT2) mutations

and mutations in DNA mismatch repair genes. Cancer

Res. 2001 Feb 15;61(4):1269-71.

337. Lee EJ, Zhao B, Seow-Choen F. Relationship between

polymorphism of N-acetyltransferase gene and

susceptibi l ity to colorectal carcinoma in a Chinese

population. Pharmacogenetics. 1998 Dec;8(6):513 -7.

338. Tamer L, Ercan B, Ates NA, Degirmenci U, Unlu A, Ates

C, et al. N-acetyltransferase 2 gene polymorphism in

patients with colorectal carcinoma. Ce ll Biochem Funct.

2006 Mar-Apr;24(2):131-5.

339. Kiss I, Nemeth A, Bogner B, Pajkos G, Orsos Z, Sandor

J, et al. Polymorphisms of glutathione -S-transferase and

arylamine N-acetyltransferase enzymes and

susceptibi l ity to colorectal cancer. Anticancer Res. 2004

Nov-Dec;24(6):3965-70.

340. Ladero JM, Gonzalez JF, Benitez J, Vargas E, Fernandez

MJ, Baki W, et al. Acetylator polymorphism in human

colorectal carcinoma. Cancer Res. 1991 Apr

15;51(8):2098-100.

341. Rodriguez JW, Kirl in WG, Ferguson RJ, Doll MA, Gray K,

Rustan TD, et al. Human acetylator genotype:

184


relat ionship to colorectal cancer incidence and arylamine

N-acetyltransferase expression in colon cytosol. Arch

Toxicol. 1993;67(7):445-52.

342. Shibuta K, Nakashima T, Abe M, Mashimo M, Mori M,

Ueo H, et al. Molecular genotyp ing for N-acetylat ion

polymorphism in Japanese patients with colorectal

cancer. Cancer. 1994 Dec 15;74(12):3108-12.

343. Probst-Hensch NM, Haile RW, Ingles SA, Longnecker

MP, Han CY, Lin BK, et al. Acetylat ion polymorphism and

prevalence of colorectal adenomas. Cancer Res. 1995

May 15;55(10):2017-20.

344. Spurr NK, Gough AC, Chinegwundoh FI, Smith CA.

Polymorphisms in drug-metabolizing enzymes as

modif iers of cancer risk. Clin Chem. 1995 Dec;41(12 Pt

2):1864-9.

345. Hubbard AL, Harrison DJ, Moyes C, Wyllie AH,

Cunningham C, Mannion E, et al. N-acetyltransferase 2

genotype in colorectal cancer and select ive gene

retention in cancers with chromosome 8p delet ions. Gut.

1997 Aug;41(2):229-34.

346. Barrett JH, Smith G, Waxman R, Gooderham N, Lightfoot

T, Garner RC, et al. Investigation of interact ion between

N-acetyltransferase 2 and heterocyclic amines as

potential r isk factors for colorectal cancer.

Carcinogenesis. 2003 Feb;24(2):275-82.

347. Slattery ML, Potter JD, Samowitz W, Bigler J, Caan B,

Leppert M. NAT2, GSTM-1, cigarette smoking, and risk of

colon cancer. Cancer Epidemiol Biomarkers Prev. 1998

Dec;7(12):1079-84.

348. Tiemersma EW, Kampman E, Bueno de Mesquita HB,

Bunschoten A, van Schothorst EM, Kok FJ, et al. Meat

consumption, cigarette smoking, and genetic

susceptibi l ity in the etiology of colorectal cancer: results

185


from a Dutch prospective study. Cancer Causes Control.

2002 May;13(4):383-93.

349. Butler WJ, Ryan P, Roberts -Thomson IC. Metabolic

genotypes and risk for colorectal cancer. J Gastroenterol

Hepatol. 2001 Jun;16(6):631-5.

350. Ye Z, Parry JM. Meta-analysis of 20 case-control studies

on the N-acetyltransferase 2 acetylat ion status and

colorectal cancer risk. Med Sci Monit. 2002

Aug;8(8):CR558-65.

351. Yu MW, Pai CI, Yang SY, Hsiao TJ, Chang HC, Lin SM,

et al. Role of N-acetyltransferase polymorphisms in

hepatit is B related hepatocellular carcinoma: impact of

smoking on risk. Gut. 2000 Nov;47(5):703-9.

352. Gao JP, Huang YD, Lin JA, Zhu QC, Liang JP.

[Relat ionship between genetic polymorphisms of N -

acetyltransferase and susceptibi l ity to hepatocellular

carcinoma]. Zhonghua Gan Zang Bing Za Zhi. 2003

Jan;11(1):20-2.

353. Farker K, Schotte U, Scheele J, Hoffmann A. Impact of

N-acetyltransferase polymorphism (NAT2) in

hepatocellular carcinoma (HCC)--an investigation in a

department of surgical medicine. Exp Toxicol Pathol.

2003 Jun;54(5-6):387-91.

354. Agundez JA, Ladero JM, Olivera M, Lozano L,

Fernandez-Arquero M, de laConcha EG, et al. N -

acetyltransferase 2 polymorphism is not related to the

risk of advanced alcoholic l iver disease. Scand J

Gastroenterol. 2002 Jan;37(1):99-103.

355. Huang YS, Chern HD, Wu JC, Chao Y, Huang YH, Chang

FY, et al. Polymorphism of the N-acetyltransferase 2

gene, red meat intake, and the susceptibil ity of

hepatocellular carcinoma. Am J Gastroenterol. 2003

Jun;98(6):1417-22.

186


356. Gelatti U, Covolo L, Talamini R, Tagger A, Barbone F,

Martell i C, et al. N-Acetyltransferase-2, glutathione S-

transferase M1 and T1 genetic polymorphisms, cigarette

smoking and hepatocellular carcinoma: a case -control

study. Int J Cancer. 2005 Jun 10;115(2) :301-6.

357. Imaizumi T, Higaki Y, Hara M, Sakamoto T, Horita M,

Mizuta T, et al. Interact ion between cytochrome P450

1A2 genetic polymorphism and cigarette smoking on the

risk of hepatocellular carcinoma in a Japanese

population. Carcinogenesis. 2009 Oct;30(10 ):1729-34.

358. Ladero JM, Fernandez MJ, Palmeiro R, Munoz JJ, Jara

C, Lazaro C, et al. Hepatic acetylator polymorphism in

breast cancer patients. Oncology. 1987;44(6):341 -4.

359. Webster DJ, Flook D, Jenkins J, Hutchings A, Routledge

PA. Drug acetylat ion in breast cancer. Br J Cancer. 1989

Aug;60(2):236-7.

360. I lett KF, Detchon P, Ingram DM, Castleden WM.

Acetylat ion phenotype is not associated with breast

cancer. Cancer Res. 1990 Oct 15;50(20):6649-51.

361. Bulovskaya LN, Krupkin RG, Bochina TA, Shipkova AA,

Pavlova MV. Acetylator phenotype in patients with breast

cancer. Oncology. 1978;35(4):185-8.

362. Sardas S, Cok I, Sardas OS, I lhan O, Karakaya AE.

Polymorphic N-acetylat ion capacity in breast cancer

patients. Int J Cancer. 1990 Dec 15;46(6):1138 -9.

363. Alberg AJ, Daudt A, Huang HY, Hoffman SC, Comstock

GW, Helzlsouer KJ, et al. N-acetyltransferase 2 (NAT2)

genotypes, cigarette smoking, and the risk of breast

cancer. Cancer Detect Prev. 2004;28(3):187-93.

364. Sil lanpaa P, Hirvonen A, Kataja V, Eskelinen M, Kosma

VM, Uusitupa M, et al. NAT2 slow acetylator genotype as

an important modif ier of breast cancer r isk. Int J Cancer.

2005 Apr 20;114(4):579-84.

187


365. Huang CS, Chern HD, Shen CY, Hsu SM, Chang KJ.

Association between N-acetyltransferase 2 (NAT2)

genetic polymorphism and development of breast cancer

in post-menopausal Chinese women in Taiwan, an area

of great increase in breast cancer incidence. Int J

Cancer. 1999 Jul 19;82(2):175-9.

366. Ambrosone CB, Kropp S, Yang J, Yao S, Shields PG,

Chang-Claude J. Cigarette smoking, N-acetyltransferase

2 genotypes, and breast cancer r isk: pooled analysis and

meta-analysis. Cancer Epidemiol Biomarkers Prev. 2008

Jan;17(1):15-26.

367. Costa S, Pinto D, Morais A, Vasconcelos A, Oliveira J,

Lopes C, et al. Acetylat ion genotype and the genetic

susceptibi l ity to prostate cancer in a southern European

population. Prostate. 2005 Aug 1;64(3):246-52.

368. Srivastava DS, Mittal RD. Genetic polymorphism of the

N-acetyltransferase 2 gene, and susceptibi l ity to prostate

cancer: a pi lot study in north Indian population. BMC

Urol. 2005;5:12.

369. Hamasaki T, Inatomi H, Katoh T, Aono H, Ikuyama T,

Muratani T, et al. N-acetyltransferase-2 gene

polymorphism as a possible biomarker for prostate

cancer in Japanese men. Int J Urol. 2003 Mar;10(3):

167-73.

370. Hein DW, Leff MA, Ishibe N, Sinha R, Frazier HA, Doll

MA, et al. Association of prostate cancer with rapid N -

acetyltransferase 1 (NAT1*10) in combination with slow

N-acetyltransferase 2 acetylator genotypes in a pilot

case-control study. Environ Mol Mutagen.

2002;40(3):161-7.

371. Agundez JA, Mart inez C, Olivera M, Gallardo L, Ladero

JM, Rosado C, et al. Expression in human prostate of

drug- and carcinogen-metabolizing enzymes: associat ion

188


with prostate cancer r isk. Br J Cancer. 1998

Nov;78(10):1361-7.

372. Wadelius M, Autrup JL, Stubbins MJ, Andersson SO,

Johansson JE, Wadelius C, et al. Polymorphisms in

NAT2, CYP2D6, CYP2C19 and GSTP1 and their

association with prostate cancer. Pharmacogenetics.

1999 Jun;9(3):333-40.

373. Sharma S, Cao X, Wilkens LR, Yamamoto J, Lum-Jones

A, Henderson BE, et al. Well-done meat consumption,

NAT1 and NAT2 acetylator genotypes and prostate

cancer r isk: the multiethnic cohort study. Cancer

Epidemiol Biomarkers Prev. 2010 Jul;19(7):1866 -70.

374. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis

and visualization of LD and haplotype maps.

Bioinformatics. 2005 Jan 15;21(2):263 -5.

375. Gabriel SB, Schaffner SF, Nguyen H, Moore JM, Roy J,

Blumenstiel B, et al. The structure of haplotype blocks in

the human genome. Science. 2002 Jun

21;296(5576):2225-9.

376. Tregouet DA, Escolano S, Tiret L, Mallet A, Golmard JL.

A new algorithm for haplotype-based associat ion

analysis: the Stochastic -EM algorithm. Ann Hum Genet.

2004 Mar;68(Pt 2):165-77.

377. Lieber CS. Cytochrome P-4502E1: its physiological and

pathological role. Physiol Rev. 1997 Apr;77(2):517-44.

378. Rendic S, Guengerich FP. Update information on drug

metabolism systems--2009, part II: summary of

information on the effects of diseases and environmental

factors on human cytochrome P450 (CYP) enzymes and

transporters. Curr Drug Metab. 2010 Jan;11(1):4-84.

379. Rendic S. Summary of information on human CYP

enzymes: human P450 metabolism data. Drug Metab

Rev. 2002 Feb-May;34(1-2):83-448.

189


380. Omiecinski CJ, Redlich CA, Costa P. Induction and

developmental expression of cytochrome P450IA1

messenger RNA in rat and human tissues: detection by

the polymerase chain reaction. Cancer Res. 1990 Jul

15;50(14):4315-21.

381. Hecht SS, Carmella SG, Murphy SE, Foiles PG, Chung

FL. Carcinogen biomarkers related to smoking and upper

aerodigestive tract cancer. J Cell Biochem Suppl.

1993;17F:27-35.

382. Schwarz D, Kisselev P, Cascorbi I, Schunck WH, Roots I.

Dif ferential metabolism of benzo[a]pyrene and

benzo[a]pyrene-7,8-dihydrodiol by human CYP1A1

variants. Carcinogenesis. 2001 Mar;22(3):453 -9.

383. Georgiadis P, Topinka J, Vlachodimitropoulos D,

Stoikidou M, Gioka M, Stephanou G, et al. Interactions

between CYP1A1 polymorphisms and exposure to

environmental tobacco smoke in the modulation of

lymphocyte bulky DNA adducts and chromosomal

aberrat ions. Carcinogenesis. 2005 Jan;26(1):93 -101.

384. Sreelekha TT, Ramadas K, Pandey M, Thomas G,

Nalinakumari KR, Pil lai MR. Genetic polymorphism of

CYP1A1, GSTM1 and GSTT1 genes in Indian oral

cancer. Oral Oncol. 2001 Oct;37(7):593-8.

385. Sikdar N, Mahmud SA, Paul RR, Roy B. Polymorphism in

CYP1A1 and CYP2E1 genes and susceptibil ity to

leukoplakia in Indian tobacco users. Cancer Lett. 2003

May 30;195(1):33-42.

386. Hahn M, Hagedorn G, Kuhlisch E, Schackert HK, Eckelt

U. Genetic polymorphisms of drug-metabolizing enzymes

and susceptibil ity to oral cavity cancer. Oral Oncol. 2002

Jul;38(5):486-90.

387. Kao SY, Wu CH, Lin SC, Yap SK, Chang CS, Wong YK,

et al. Genetic polymorphism of cytochrome P4501A1 and

190


susceptibi l ity to oral squamous cell carcinoma and oral

precancer lesions associated with smoking/betel use. J

Oral Pathol Med. 2002 Oct;31(9):505-11.

388. Xie H, Hou L, Shields PG, Winn DM, Gridley G, Bravo -

Otero E, et al. Metabolic polymorphisms, smoking, and

oral cancer in Puerto Rico. Oncol Res. 2004;14(6):

315-20.

389. Sugimura T, Kumimoto H, Tohnai I, Fukui T, Ma tsuo K,

Tsurusako S, et al. Gene-environment interact ion

involved in oral carcinogenesis: molecular

epidemiological study for metabolic and DNA repair gene

polymorphisms. J Oral Pathol Med. 2006 Jan;35(1):11 -8.

390. Marques CF, Koifman S, Koifman RJ, Boffetta P ,

Brennan P, Hatagima A. Inf luence of CYP1A1, CYP2E1,

GSTM3 and NAT2 genetic polymorphisms in oral cancer

susceptibi l ity: results from a case-control study in Rio de

Janeiro. Oral Oncol. 2006 Jul;42(6):632-7.

391. Leichsenring A, Losi -Guembarovski R, Maciel ME, Losi-

Guembarovski A, Oliveira BW, Ramos G, et al. CYP1A1

and GSTP1 polymorphisms in an oral cancer case -

control study. Braz J Med Biol Res. 2006 Dec; 39

(12):1569-74.

392. Losi-Guembarovski R, Colus IM, De Menezes RP,

Poliseli F, Chaves VN, Kuasne H, et al. Lack of

association among polymorphic xenobiotic -metabolizing

enzyme genotypes and the occurrence and progression

of oral carcinoma in a Brazil ian population. Anticancer

Res. 2008 Mar-Apr;28(2A):1023-8.

393. Buch SC, Nazar-Stewart V, Weissfeld JL, Romkes M.

Case-control study of oral and oropharyngeal cancer in

whites and genetic variation in eight metabolic enzymes.

Head Neck. 2008 Sep;30(9):1139-47.

191


394. Amtha R, Ching CS, Zain R, Razak IA, Basuki B, Roeslan

BO, et al. GSTM1, GSTT1 and CYP1A1 polymorphisms

and risk of oral cancer: a case-control study in Jakarta,

Indonesia. Asian Pac J Cancer Prev. 2009 Jan -Mar;

10(1):21-6.

395. Cha IH, Park JY, Chung WY, Choi MA, Kim HJ, Park KK.

Polymorphisms of CYP1A1 and GSTM1 genes and

susceptibi l ity to oral cancer. Yonsei Med J. 2007 Apr

30;48(2):233-9.

396. Anantharaman D, Chaubal PM, Kannan S, Bhisey RA,

Mahimkar MB. Susceptibil ity to oral cancer by genetic

polymorphisms at CYP1A1, GSTM1 and GSTT1 loci

among Indians: tobacco exposure as a risk modulator.

Carcinogenesis. 2007 Jul;28(7):1455-62.

397. Lee MY, Mukherjee N, Pakstis AJ, Khaliq S, Mohyuddin

A, Mehdi SQ, et al. Global patterns of variation in al lele

and haplotype frequencies and linkage disequil ibrium

across the CYP2E1 gene. Pharmacogenomics J. 2008

Oct;8(5):349-56.

398. Kidd KK, Morar B, Castiglione CM, Zhao H, Pakstis AJ,

Speed WC, et al. A global survey of haplotype

frequencies and l inkage disequil ibrium at the DRD2

locus. Hum Genet. 1998 Aug;103(2):211-27.

399. Bouchardy C, Hirvonen A, Coutelle C, Ward PJ, Dayer P,

Benhamou S. Role of alcohol dehydrogenase 3 and

cytochrome P-4502E1 genotypes in susceptibi l ity to

cancers of the upper aerodigestive tract. Int J Cancer.

2000 Sep 1;87(5):734-40.

400. Liu S, Park JY, Schantz SP, Stern JC, Lazarus P.

Elucidation of CYP2E1 5' regulatory RsaI/Pstl allelic

variants and their role in risk for oral cancer. Oral Oncol.

2001 Jul;37(5):437-45.

192


401. Zavras AI, Wu T, Laskaris G, Wang YF, Cartsos V, Segas

J, et al. Interaction between a single nucleotide

polymorphism in the alcohol dehydrogenase 3 gene,

alcohol consumption and oral cancer risk. Int J Cancer.

2002 Feb 1;97(4):526-30.

402. Liu TY, Chung YT, Wang PF, Chi CW, Hsieh LL. Safrole -

DNA adducts in human peripheral blood--an associat ion

with areca quid chewing and CYP2E1 polymorphisms.

Mutat Res. 2004 Apr 11;559(1-2):59-66.

403. Soya SS, Vinod T, Reddy KS, Gopalakrishnan S, Adithan

C. CYP2E1 polymorphisms and gene-environment

interactions in the risk of upper aerodigestive tract

cancers among Indians. Pharmacogenomics. 2008

May;9(5):551-60.

404. Tang K, Li Y, Zhang Z, Gu Y, Xiong Y, Feng G, et al. The

PstI/RsaI and DraI polymorphisms of CYP2E1 and head

and neck cancer risk: a meta-analysis based on 21 case-

control studies. BMC Cancer. 2010;10:575.

405. Garte S, Gaspari L, Alexandrie AK, Ambrosone C, Autrup

H, Autrup JL, et al. Metabolic gene polymorphism

frequencies in control populations. Cancer Epidemiol

Biomarkers Prev. 2001 Dec;10(12):1239-48.

406. Wenghoefer M, Pesch B, Harth V, Broede P, Fronhoffs S,

Landt O, et al. Association between head and neck

cancer and microsomal epoxide hydrolase genotypes.

Arch Toxicol. 2003 Jan;77(1):37-41.

407. Varela-Lema L, Ruano-Ravina A, Juiz Crespo MA, Kelsey

KT, Loidi L, Barros-Dios JM. CYP1A1, mEH, and GSTM1

Polymophisms and Risk of Oral and Pharyngeal Cancer:

A Spanish Case-Control Study. J Oncol.

2008;2008:741310.

408. Boccia S, Cadoni G, Sayed-Tabatabaei FA, Volante M,

Arzani D, De Lauretis A, et al. CYP1A1, CYP2E1,

193


GSTM1, GSTT1, EPHX1 exons 3 and 4, and NAT2

polymorphisms, smoking, consumption of alcohol and

fruit and vegetables and risk of head and neck cancer. J

Cancer Res Clin Oncol. 2008 Jan;134(1):93 -100.

409. Heckbert SR, Weiss NS, Hornung SK, Eaton DL,

Motulsky AG. Glutathione S-transferase and epoxide

hydrolase act ivity in human leukocytes in relation to r isk

of lung cancer and other smoking-related cancers. J Natl

Cancer Inst. 1992 Mar 18;84(6):414-22.

410. Timofeeva M, Kropp S, Sauter W, Beckmann L,

Rosenberger A, I l l ig T, et al. Genetic polymorphisms of

MPO, GSTT1, GSTM1, GSTP1, EPHX1 and NQO1 as risk

factors of early-onset lung cancer. Int J Cancer. 2010

Oct 1;127(7):1547-61.

411. Robien K, Curt in K, Ulrich CM, Bigler J, Samowitz W,

Caan B, et al. Microsomal epoxide hydrolase

polymorphisms are not associated with colon cancer r isk.

Cancer Epidemiol Biomarkers Prev. 2005

May;14(5):1350-2.

412. Voho A, Metsola K, Antti la S, Impivaara O, Jarvisalo J,

Vainio H, et al. EPHX1 gene polymorphisms and

individual susceptibil ity to lung cancer. Cancer Lett. 2006

Jun 8;237(1):102-8.

413. Wu X, Gwyn K, Amos CI, Makan N, Hong WK, Spitz MR.

The associat ion of microsomal epoxide hydro lase

polymorphisms and lung cancer risk in African -Americans

and Mexican-Americans. Carcinogenesis. 2001 Jun;

22(6):923-8.

414. Lee J, Nordestgaard BG, Dahl M. EPHX1 polymorphisms,

COPD and asthma in 47,000 individuals and in meta -

analysis. Eur Respir J. 2010 Jun 1.

415. Chappell S, Daly L, Morgan K, Guetta -Baranes T, Roca

J, Rabinovich R, et al. Genetic variants of microsomal

194


epoxide hydrolase and glutamate-cysteine l igase in

COPD. Eur Respir J. 2008 Oct;32(4):931-7.

416. Yang X, Liang SH, Weyant DM, Lazarus P, Gallagher CJ,

Omiecinski CJ. The expression of human microsomal

epoxide hydrolase is predominantly driven by a

genetical ly polymorphic far upstream promoter. J

Pharmacol Exp Ther. 2009 Jul;330(1):23-30.

417. Hughes HB, Biehl JP, Jones AP, Schmidt LH. Metabolism

of isoniazid in man as related to the occurrence of

peripheral neurit is. Am Rev Tuberc. 1954 Aug;70(2):

266-73.

418. Weber WW, Hein DW. N-acetylat ion pharmacogenetics.

Pharmacol Rev. 1985 Mar;37(1):25-79.

419. Song DK, Xing DL, Zhang LR, Li ZX, Liu J, Qiao BP.

Association of NAT2, GSTM1, GSTT1, CYP2A6, and

CYP2A13 gene polymorphisms with susceptibi l i ty and

clinicopathologic characteristics of bladder cancer in

Central China. Cancer Detect Prev. 2009;32(5 -6):416-23.

420. Yoshida K, Osawa K, Kasahara M, Miyaishi A, Nakanishi

K, Hayamizu S, et al. Association of CYP1A1, CYP1A2,

GSTM1 and NAT2 gene polymorphisms with colorectal

cancer and smoking. Asian Pac J Cancer Prev. 2007 Jul -

Sep;8(3):438-44.

421. Nikishina MV, Vavilin VA, Makarova SI, Lyakhovich VV.

Analysis of associations of NAT2 gene polymorphisms

with the risk of lung cancer. Bull Exp Biol Med. 2007

Jan;143(1):83-6.

422. Drozdz M, Gierek T, Jendryczko A, Pilch J, Piekarska J.

N-acetyltransferase phenotype of patients with cancer of

the larynx. Neoplasma. 1987;34(4):481 -4.

423. Gonzalez MV, Alvarez V, Pello MF, Menendez MJ,

Suarez C, Coto E. Genetic polymorphism of N-

acetyltransferase-2, glutathione S-transferase-M1, and

195


cytochromes P450IIE1 and P450IID6 in the susceptibi l ity

to head and neck cancer. J Clin Pathol. 1998

Apr;51(4):294-8.

424. Henning S, Cascorbi I, Munchow B, Jahnke V, Roots I.

Association of arylamine N-acetyltransferases NAT1 and

NAT2 genotypes to laryngeal cancer risk.

Pharmacogenetics. 1999 Feb;9(1):103 -11.

425. Jourenkova-Mironova N, Wikman H, Bouchardy C,

Mitrunen K, Dayer P, Benhamou S, et al. Role of

arylamine N-acetyltransferase 1 and 2 (NAT1 and NAT2)

genotypes in susceptibil ity to oral/pharyngeal and

laryngeal cancers. Pharmacogenetics. 1999 Aug; 9(4):

533-7.

426. Katoh T, Kaneko S, Boissy R, Watson M, Ikemura K, Bell

DA. A pilot study testing the associat ion between N-

acetyltransferases 1 and 2 and risk of oral squamous cell

carcinoma in Japanese people. Carcinogenesis. 1998

Oct;19(10):1803-7.

427. Morita S, Yano M, Tsujinaka T, Akiyama Y, Taniguchi M,

Kaneko K, et al. Genetic polymorphisms of drug-

metabolizing enzymes and susceptibil ity to head -and-

neck squamous-cell carcinoma. Int J Cancer. 1999 Mar

1;80(5):685-8.

428. Chen C, Ricks S, Doody DR, Fitzgibbons ED, Porter PL,

Schwartz SM. N-Acetyltransferase 2 polymorphisms,

cigarette smoking and alcohol consumption, and oral

squamous cell cancer r isk. Carcinogenesis. 2001

Dec;22(12):1993-9.

429. Canova C, Hashibe M, Simonato L, Nelis M, Metspalu A,

Lagiou P, et al. Genetic associations of 115

polymorphisms with cancers of the upper aerodigestive

tract across 10 European countries: the ARCAGE project.

Cancer Res. 2009 Apr 1;69(7):2956-65.

138 - shodhgangashodhganga.inflibnet.ac.in/.../16/16_references.pdf · stewart fa. photodynamic...

Documents